Drug, bio-affecting and body treating compositions inventions 02/07

20070042935 - Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect: The subject of the present invention are quinazoline derivatives and their pharmaceutically acceptable salts of general formula (I), that inhibit a DNA-repairing enzyme, poly(ADP-ribose) polymerase (PARP), enabling them to be used for the preparation of pharmaceutical compositions for preventing or treating illnesses where PARP-inhibition yields a beneficial effect. In general... Agent: Young & Thompson

20070042936 - Multivalent inhibitors of serum amyloid p component: Novel glycerol cyclic pyruvate derivates were prepared and demonstrated to inhibit the binding of an immobilized D-proline derivative to serum amyloid P component (SAP) have been prepared. As such, the compounds of the invention are useful for treating amyloidosis and diseases associated with amyloidosis, for example Alzheimer&supl;s disease and maturity... Agent: Foley & Lardner LLP

20070042937 - Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers: The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g.,... Agent: Fibrogen, Inc. Intellectual Property Department

20070042940 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070042939 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070042938 - Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts: The invention relates to a process for the inhibition of the DNA synthesis (essential for the proliferation) of human fibroblasts by a single or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipeptidyl peptidase IV (DPIV) expressed by those cells. The DNA synthesis (proliferation) of human fibroblasts is inhibited,... Agent: Hodgson Russ LLP

20070042941 - Galectin 9-inducing factors: It has been disclosed that Galectin 9, which is a physiologically active substance acting as a lectin, is expressed in various cells and a correlationship is observed between the expression level of galectin 9 and the metastatic ability of tumors. Therefore, it is presumed that galectin 9 would relate to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070042942 - Glycopeptide carboxy-saccharide derivatives: Disclosed are glycopeptide derivatives substituted at the C-terminus and/or the R-terminus with a substituent that comprises one or more saccharide groups and a carboxy group; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.... Agent: Theravance, Inc.

20070042943 - Novel cyclosporin galenic forms: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.... Agent: Novartis Corporate Intellectual Property

20070042955 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Hunton & Williams LLP Intellectual Property Department

20070042961 - Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity: Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Three examples of such recombinant APC mutants are KKK191-193AAA-APC, RR229/230AA-APC, and RR229/230AA plus KKK191-193AAA-APC.... Agent: Morgan & Finnegan, L.L.P.

20070042947 - Agents for preventing and/or treating uppper digestive tract disorders: A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which... Agent: Edwards & Angell, LLP

20070042952 - Analogues of glp-1: Disclosed are peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, methods of using such analogues to treat mammals and pharmaceutical compositions useful therefor comprising said analogues.... Agent: Brian R Morrill Biomeasure Incorporated

20070042950 - Antagonistic analogs of gh rh (2003): There is provided a novel series of synthetic antagonistic analogs of hGH-RH(1-29)NH2. These analogs inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors, and therefore prevent the release of growth hormone. The analogs also inhibit the proliferation of human cancers through a direct effect on the cancer cells.... Agent: Omri M. Behr

20070042953 - Antiepileptogenic complex of albumin with docosahexaenoate: The infusion of an albumin-docosahexaenoic acid (DHA) complex was shown to inhibit the progression of kindling epileptogenesis. This was shown in mice using kindling as the experimental epilepsy model. The DHA-albumin complex was shown to affect the activity of the brain when administered intraperitoneally. This therapy could also be administered... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20070042954 - Compositions and methods related to soluble g-protein coupled receptors (sgpcrs): The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In ceratin aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand... Agent: Fulbright & Jaworski, L.L.P.

20070042958 - Lefty, lefty derivatives and uses thereof: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070042960 - Methods of using zven proteins: The present invention provides novel uses two members of a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes. The... Agent: Zymogenetics, Inc. Intellectual Property Department

20070042945 - Nouvelles compositions et methods de traitement du psoriasis: The present invention relates to compositions and methods useful for the diagnosis and treatment of psoriasis.... Agent: Genentech, Inc.

20070042956 - Novel glp-1 compounds: Novel GLP-1 compounds and their therapeutic use.... Agent: Novo Nordisk, Inc. Patent Department

20070042946 - Peptide inhibitors of thrombin as potent anticoagulants: The tetrapeptide Phe-Asn-Pro-Arg is a structurally-optimized sequence for binding to the active site of thrombin. By conjugating this tetrapeptide or variants thereof to a C-terminal fragment of hirudin, we were able to generate a series of new multivalent inhibitors of thrombin containing only genetically encodable natural amino acids. We found... Agent: Ogilvy Renault LLP

20070042951 - Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides: Disclosed herein are dosage forms comprising an alpha-2-adrenergic agonist and a trefoil factor family peptide. Related to these dosage forms are methods of treating glaucoma or reducing intraocular pressure and methods of treating gastrointestinal disorders.... Agent: Allergan, Inc.

20070042949 - Pharmaceutical compositions comprising an epitope of platelet gpiiia protein: The present invention relates to a pharmaceutical composition for the prevention or management of a condition caused by exposure to an antithetical allele of a platelet by tolerisation, the composition comprising an immunologically effective platelet protein or peptide fragment thereof.... Agent: Licata & Tyrrell P.C.

20070042944 - Processes for the preparation of fibrinogen: The present invention relates to processes for the purification of fibrinogen, and to readily solubilised fibrinogen preparations.... Agent: Knobbe Martens Olson & Bear LLP

20070042959 - Thrombin-inhibiting peptides: Peptides of Formula I are useful for therapeutic purposes, among others.... Agent: Millen, White, Zelano & Branigan, P.C.

20070042957 - Type v phosphodiesterase inhibitors and natriuretic polypeptides: This document provides methods and materials related to PDE V inhibitors, natriuretic polypeptides, and combinations thereof. For example, compositions containing one or more PDE V inhibitors in combination with one or more natriuretic polypeptides are provided herein. In addition, methods for using PDE V inhibitors, natriuretic polypeptides, and combinations thereof... Agent: Fish & Richardson P.C.

20070042948 - Vav inhibition in graft rejection: The present invention provides a method for preventing or treating acute or chronic graft rejection in a recipient of cell, tissue or organ allo- or xenotransplant, inflammatory or autoimmune diseases or malignant proliferative disease, comprising the use of an inhibitor of Vav. Further provided are Vav inhibitors, uses, pharmaceutical compositions... Agent: Novartis Corporate Intellectual Property

20070042962 - Peptide dependent upregulation of telomerase expression: Methods and compositions comprising peptide compounds are described to upregulate expression of telomerase in eukaryotic cells, tissues, and organs. Such methods and compositions are particularly useful in treating diseases, trauma, and conditions of the aging process.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070042963 - Therapeutic peptides: The invention provides peptides of about 9-12 amino acids having a sequence derived from the interferon binding site of the IFNAR1 chain of the Type 1-interferon (Type 1-IFN) receptor for use as a Type 1-IFN antagonist. In particular, the invention provides peptides having the 9 mer sequence FSSLKLNVY (SEQ ID... Agent: Baker Botts, LLP

20070042964 - Compositions and methods for modulating connexin hemichannels: Disclosed are compositions and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compounds, particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a... Agent: Fitzpatrick Cella Harper & Scinto

20070042965 - Crystallized structure of type iv collagen nc1 domain hexamer: The present invention provides a crystallized NC1 domain hexamer of Type IV collagen, and methods for making the crystal, wherein the NC1 domain hexamer is crystallized such that the three dimensional structure of the crystallized NC1 domain hexamer can be determined to a resolution of at least 3 Å or... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070042966 - Inhibition of cell motility, angiogenesis, and metastasis: Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by inhibiting hepatocyte growth factor (HGF) induced cell motility. The present invention also provides a method of inhibiting angiogenesis. The methods of the present... Agent: Leydig, Voit & Mayer, Ltd.

20070042967 - Proteaseome inhibitors for the treatment of herpesviridae infected individuals: The present invention relates to the use of a substance or composition comprising one or more proteasome inhibitors for the manufacture of a medicament for the treatment of an individual infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, human herpesvirus 6 and 7 and... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070042969 - Combination therapy for pain in painful diabetic neuropathy: A method for treating pain in painful diabetic neuropathy comprises administering in combination a first agent that comprises a compound as defined herein, illustratively lacosamide, and a second agent effective to provide enhanced treatment of pain, by comparison with the first agent alone. The second agent illustratively comprises an analgesic,... Agent: Harness, Dickey, & Pierce, P.l.c

20070042968 - Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070042970 - Folate-modified cholesterol-bearing pullulan as a drug carrier: Folate modified cholesterol-bearing pullulan (FA-CHP) was synthesized by the reaction of folic acid γ-2-aminoethylamide and 4-nitorophenyl chloroformate-activated cholesterol-bearing pullulan, wherein folate and pullulan are connected through a NH—CH2—CH2—NH group. Approximately 0.5-1 folates are connected per about 100 glycoside units of pullulan. Then, several combinations of FA-CHP, cholesterol-bearing pullulan (CHP) and... Agent: Oliff & Berridge, PLC

20070042972 - Compositions and methods for optimizing exercise recovery: The present invention provides methods for decreasing post-exercise recovery time in a subject using compositions comprising one or more polymethoxylated flavones (PMFs). In preferred embodiments, the composition is an orange peel extract as described herein. In certain embodiments, post-exercise recovery time is the time for a subject's post-exercise oxygen consumption... Agent: Jones Day

20070042971 - Crystalline compound of 4'-demethyl-4'-phosphate-2\", 3\"-bispentafluorophenoxy-acetyl-4\", 6\"-ethylidene-beta-d-epipodophyllotoxin glucoside either in its free form or solvated with ethanol: The invention relates to a crystalline compound of 4′-demethyl-4′-phosphate-2″,3″-bispentafluorophenoxyacetyl-4″,6″-ethylidene-β-D-epipodophyllotoxin glucoside in its free form or solvated with ethanol, advantageously provided in the form of a hemiethanolate solvate. The invention also relates to a method for preparing these compounds and to their use as an anticancer drug.... Agent: Birch Stewart Kolasch & Birch

20070042973 - Treatment of pain and fever: This invention relates to a method of treating, decreasing, or preventing pain or fever comprising administering to a subject in need thereof a composition comprising the inventive compounds.... Agent: Nada Jain, P.C.

20070042974 - Nozel azalide and azalactam derivatives and method for producing the same: [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an... Agent: Greenblum & Bernstein, P.L.C

20070042976 - Method of treating cosmetic and dermatologic conditions by a demethylating agent: A method for the treatment of scars and keloids is disclosed. The treatment involves an effective dose of the demethylating agents, 5-azacytidine and 2-deoxy-5-azacytidine. The method also discloses treating skin cancer with a combination therapy comprised of UV radiation and topical application or administration of the above mentioned demethylating agents.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070042975 - Novel indolopyrrolocarbazole derivative with antitumor activity: R2 represents a phenyl group, a naphthyl group, or a five- or six-membered aromatic or aliphatic heterocyclic ring having at least one atom selected from N, S, or O, wherein the phenyl group, naphthyl group, aromatic or aliphatic heterocyclic ring may be substituted; and G represents a hexose group or... Agent: Merck And Co., Inc

20070042985 - Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.... Agent: Young & Thompson

20070042982 - Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known... Agent: Howrey LLP

20070042980 - Gp131: methods and compositions for treating cancer: The use of molecules relating to the GP131 (ceramide kinase) gene for treating cancer and other hyperproliferative conditions is disclosed. Non-human mammals harboring a genetic modification relating to the GP131 gene, and their use as experimental cancer models, are disclosed.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070042986 - Methods of inhibiting vegf-c: The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C in cells (e.g., cancer cells).... Agent: Viksnins Harris & Padys Pllp

20070042978 - Nf-hev compositions and methods of use: Aspects of the present invention relate to NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor polynucleotides and polypeptides expressed in endothelial cells from chronically inflamed tissues, particularly in high... Agent: Knobbe Martens Olson & Bear LLP

20070042979 - Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite: The present invention provides a complex, which comprises a cationic liposome comprising 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and a phospholipid as main ingredients, and an oligo nucleic acid which is carried on the liposome. Also, the present invention provides a pharmaceutical composition containing the complex to be used for treating or preventing diseases caused... Agent: Darby & Darby P.C.

20070042983 - Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070042984 - Rnai modulation of the rho-a gene and uses thereof: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.... Agent: Fish & Richardson PC

20070042981 - Use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases: The present invention relates to the significant functional role of several C. elegans genes and of their corresponding gene products in chromatin separation during cell division that could be identified by means of RNA-mediated interference (RNAi) and to the identification and isolation of functional orthologs of said genes including all... Agent: Connolly Bove Lodge & Hutz, LLP

20070042977 - Vaccine: The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070042988 - Antiviral phosphoramidates: The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070042989 - Novel 2'-c-methyl nucleoside derivatives: Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070042987 - Stereoselective synthesis of beta-nucleosides: m

20070042990 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070042991 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070042992 - Inulin products with improved nutritional properties: The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects/benefits, as well... Agent: Hayes, Soloway P.C.

20070042993 - Polysaccharides derivatives with high antithrombotic activity in plasma: The present invention relates to a process for the preparation of sulphated glycosaminoglycans derived from N-acetylheparosan which comprises: a) N-deacetylation and N-sulphation of the N-acetylheparosan polysaccharide prepared from natural or recombinant bacterial strain, preferably K5 E. coli, b) enzymatic epimerization with the glucuronyl C5-epimerase enzyme, c) partial O-sulphation followed by... Agent: Jay S Cinamon Abelman Frayne & Schwab

20070042994 - Pharmaceutical compositions comprising peranhydrocyclodextrin: The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.... Agent: Novartis Corporate Intellectual Property

20070042995 - Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria: The present invention discloses a use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating local lesions or systematic symptoms caused by infections of virus or bacteria. A parenteral preparation comprising N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof as active component is capable of controlling... Agent: Seed Intellectual Property Law Group PLLC

20070042997 - Medicament for treatment of dermal pigmentation: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z... Agent: Greenblum & Bernstein, P.L.C

20070042996 - N-alkynyl-2-(substituted aryloxy) alkylthioamine derivatives as fungicides: Fungicidal compounds of the general formula (1), wherein Ar is a group of the formula (A), (B1), (B2) or (C), or Ar is a 5- or 6-linked group of the formula (D1) or (D2); and R1, R2, R3, R4, R5, n, A1, A2, A3, A4, A5, Ka, Kb, L, M,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070042998 - Medical cosmetic method for reducing adipose tissue and for initiating lipolysis through subcutaneous and intracutaneous injections and customized composition compounded from pharmaceutical agents for use therein: The invention describes a method and pharmaceutical compositions for subcutaneous and intracutaneous injection for reduction of localized fat deposits comprising the use of (3-sn-Phosphatidyl)-cholin as a main active and supporting ingredient either on its own, diluted or in combination with compounded agents to initiate the process of lipolysis of the... Agent: Ronald E. Greigg Greigg & Greigg P.l.l.c.

20070043000 - Immunosuppresive effects of pteridine derivatives: Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS... Agent: Clark & Elbing LLP

20070042999 - Phosphate derivatives of pharmaceutical products: According to the invention, there is provided a complex of a pharmaceutical compound selected from the group consisting of opioids, hormones, anaethetics and chemotherapeutic agents comprising the reaction product of: (a) one or more phosphate derivatives of one or more opioids, steroid hormones, thyroid hormones, anaesthetics or chemotherapeutic agents having... Agent: Reed Smith LLP

20070043001 - Inhibitors of akt activity: The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20070043002 - Aldolase-inhibiting aromatic compounds: The invention relates to novel aldolase-inhibiting compounds that can be advantageously used as medicaments (in therapeutic doses), especially for treating certain cancers, due to the inhibition efficacy thereof. An inventive compound corresponds to general formula (I) wherein the aldehyde group (—CHO) and the phenol group (—OH) are linked to two... Agent: Clark & Elbing LLP

20070043003 - Novel compounds for the prophylaxis and treatment of inflammatory bowel diseases: Novel compounds are disclosed for the prophylaxis and treatment of inflammatory bowel disease (IBD) via the administration of an effective amount in a suitable pharmaceutical dosage of agents that are active by themselves or can deliver tin the large intestine active forms of the drugs such as 5ASA or benzoxazole... Agent: Miller, Matthias & Hull

20070043004 - High drug load mesalazine sachet: The present invention is directed to a high drug formulation having desirable properties in terms of ease of manufacture and visual appearance as well as a sachet for the formulation.... Agent: Foley And Lardner LLP Suite 500

20070043005 - Treatment of hyperproliferative diseases using high doses of active vitamin d: The present invention provides a method of inhibiting the hyperproliferative cellular activity of neoplasms and other hyperproliferative diseases with an active vitamin D compound utilizing a high dose, episodic treatment protocol.... Agent: Michael Best & Friedrich, LLP

20070043006 - Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis: Methods for the use of NSAIs in combination with anecortave acetate are disclosed for preventing and treating pathologic ocular angiogenesis and associated edema, retinal edema, PPDR or NPDR.... Agent: Teresa J Schultz Alcon Research

20070043007 - Specific glucocorticosteroid compounds having anti-inflammatory activity: t

20070043008 - Condensed bicyclo[3.1.0] hex-4-en derivatives useful as antibacterial agents: According to a first aspect of the present invention there is provided a compound of formula (I): where, A is carbon, sulphur, oxygen or nitrogen B is carbon or nitrogen, X is oxygen or sulphur, Y is hydrogen, a halogen, a substituted or unsubstituted heterocyclic moiety, substituted or unsubstituted, linear... Agent: Fish & Richardson P.C.

20070043012 - Methods to enhance chemotherapy: Antagonists of the interaction of CXCR4 receptor with its ligand enhance the effectiveness of chemotherapeutic methods in subjects afflicted with myeloid or hematopoietic malignancies.... Agent: Morrison & Foerster LLP

20070043010 - Quinazoline derivatives: The invention concerns a quinazoline derivative of the Formula (I): wherein each of the variables have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention... Agent: Morgan Lewis & Bockius LLP

20070043009 - Quinazoline derivatives as tyrosine kinase inhibitors: The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The... Agent: Morgan Lewis & Bockius LLP

20070043011 - Substituted benzanilide compound and noxious organism controlling agent:  wherein W1 and W2 each independently represent an oxygen atom or a sulfur atom, X represents a halogen atom, etc., Y represents C1 to C6 alkyl, etc., R1 represents C1 to C12 alkyl, a C1 to C6 alkylthio(C1 to C6) alkyl, a C1 to C6 alkylsulfinyl(C1 to C6) alkyl or... Agent: Manelli Denison & Selter

20070043013 - 1,3 disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases: in free or salt form, wherein Ar, X1, X2, m, R1, Q, Y, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. Pharmaceutical compositions... Agent: Novartis Corporate Intellectual Property

20070043017 - Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070043018 - 2\"-hydroxynicotianamine, process for producing the same and angiotensin converting enzyme inhibitor, hypotensive drug and health food: The invention provides 2″-hydroxynicotianamine; a method for producing 2″-hydroxynicotianamine comprising the step of obtaining an extract solution from a buckwheat sample followed by obtaining a fraction having an inhibitory activity for the angiotensin-converting enzyme by ion-exchange chromatography using an anion exchange resin; novel substances having an ACE inhibitory activity by... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043014 - 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists: The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.... Agent: Merck And Co., Inc

20070043016 - Method of treating fibrotic diseases or other indications with imidazolium agents: e

20070043015 - Phenyl pyrrolidine ether tachykinin receptor antagonists: The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their... Agent: Merck And Co., Inc

20070043019 - Salt and crystalline forms thereof of a drug: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070043020 - Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds: provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity,... Agent: Novartis Corporate Intellectual Property

20070043021 - Olanzapine analogs and methods of use thereof: The invention relates to novel compounds and methods of using them for modulating sleep.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070043022 - Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication: a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C1-10alkanediyl; R1 is Ar1 or a monocyclic or bicyclic heterocycle Q is R7, pyrrolidinyl substituted with R7, piperidinyl substituted with R7 or homopiperidinyl substituted with R7; one... Agent: Philip S. Johnson Johnson & Johnson

20070043023 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20070043024 - Azacyclic compounds as inhibitors of sensory neurone specific channels: Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents wherein: X is —N— or —CH—; n is from 0 to 3.... Agent: Nixon & Vanderhye, PC

20070043025 - Method of treating dry eye disease with non-drying antihistamines: A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the eyes of the subject a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms... Agent: Howery LLP

20070043026 - Dopamine receptor modulators as antipsychotic agents: m

20070043027 - Sulfonamide derivatives for the treatment of diabetes: The present invention is related to the use of sulfonamide derivatives in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS). Formula (I). R1 is selected from the group comprising or consisting of hydrogen,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043028 - Compositions of novel opioid compounds and method of use thereof: Diarylmethylpiperazine compounds are described, which are useful as mu and/or delta receptor opioid compounds, without central side effects. Pharmaceutical compositions containing such compounds are variously useful for peripheral or non-centrally mediated indications, including peripherally mediated and neuropathic pain, urogenital tract disorders, overactive bladder, urinary incontinence, sexual disorders, premature ejaculation, cough,... Agent: Moore & Van Allen PLLC

20070043029 - 11-phenyl-dibenzodiazepine derivatives as rxr-antagonists: The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, for delaying progression of, preventing or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.... Agent: Novartis Corporate Intellectual Property

20070043034 - Chlorine ion uptake modulators and uses thereof: The present invention provides methods for using chloride ion uptake modulators to treat disorders that are mediated by a sodium/potassium/chloride cotransporter.... Agent: Faegre & Benson LLP Patent Docketing

20070043032 - Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist: A composition comprising a benzodiazepine agonist, a benzodiazepine antagonist, and a pharmaceutical acceptable carrier in an effective ratio so as to preserve the therapeutic effects of the benzodiazepine agonist while modulating the side effects of the benzodiazepine agonist.... Agent: The Bilicki Law Firm, PC

20070043031 - Non-amide nonanes: and pharmaceutically-acceptable salts thereof, wherein Q, E and D are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070043030 - Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation: The present invention relates to improved formulations for the treatment of premature ejaculation and, in particular, relates to the administration of antidepressants by pulmonary inhalation for treating premature ejaculation. Various types of known antidepressants may be used, including tricyclic antidepressants, such as clomipramine.... Agent: Davidson, Davidson & Kappel, LLC

20070043033 - Unsolvated benzodiazepine compositions and methods: The present invention relates to systems and methods for generating new forms of benzodiazepine and benzodiazepine related compounds as well as new compounds and formulations generated by such methods. In particular, the present invention provides high throughput systems and methods for generating and identifying new crystalline benzodiazepine and benzodiazepine related... Agent: Medlen & Carroll, LLP

20070043035 - Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them: The present invention relates to novel hypolipidemic, antiobesity, hypocholesterolemic and antidiabetic compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their stereoisomers, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them where all symbols are as defined in the description.... Agent: Milagros A. Cepeda Dr. Reddy's Laboratories, Inc.

20070043036 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in... Agent: Morgan Lewis & Bockius LLP

20070043037 - Pyrimidine derivatives as orexin receptor antagonists: The present invention relates to the orexin receptor antagonists of the general formula (I), which are selective to orexin I receptors.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070043038 - Indolone-acetamide derivatives, processes for preparing them and their uses: The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070043039 - Substituted quinobenzoxazine analogs: e

20070043043 - Benzimidazole derivates: preparation and pharmaceutical applications: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or... Agent: Connolly Bove Lodge & Hutz LLP

20070043041 - Indol-6 sulfonamide derivative, their preparation and their use 5-ht-6 as modulators: The present invention refers to new sulfonamide derivatives, of general formula (la, lb, lc) optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, at any mixing ratio or... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043040 - Inhibitors of akt (protein kinase b): The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.... Agent: Eli Lilly & Company

20070043042 - Quinoline potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20070043044 - Pyrimidothiophene compounds: Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer wherein R2 is a group of formula —(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk′ and Alk 2 are optionally substituted divalent... Agent: Banner & Witcoff

20070043045 - Novel high affinity thiophene-based and furan-based kinase ligands: Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070043046 - Biaromatic ligand activators of ppargamma receptors: h

20070043047 - Fungicidal mixtures for controlling rice pathogens:

20070043048 - 2-aminopyrimidine derivatives and their medical use: A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound... Agent: Novartis Corporate Intellectual Property

20070043051 - Methods and compositions of novel triazine compounds: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070043050 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070043049 - Substituted heterocyclic diarylamine analogues: Substituted heterocyclic diarylamine analogues of Formula I are provided: wherein X, Y and Z are independently N or optionally substituted C, and other variables are as described in the specification. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are... Agent: Edwards & Angell, LLP

20070043053 - Pyrrolo-triazine aniline compounds useful as kinase inhibitors: b

20070043052 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20070043055 - Dihydropteridinones in the treatment of respiratory diseases: n

20070043054 - Enzyme cofactor combination for supplementing pyruvate dehydrogenase and alpha ketogluterate dehydrogenase complexes: The present invention provides a method and pharmaceutical composition for preventing or treating the development of syndromes related to dysfunctional energy metabolism, such as neuropathy, spontaneous nocturnal muscle cramps associated with neuropathy, seizuring, diabetes mellitus; pediatric hypoglycemia; myopathy; muscle fatigue; muscle spasms; somnolence; reduced mental acuity; exercise intolerance and myocardial... Agent: The Webb Law Firm, P.C.

20070043057 - Lonidamine analogs: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.... Agent: Townsend And Townsend And Crew, LLP

20070043056 - 5-substituted-2-arylpyrazines: Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well... Agent: Edwards & Angell, LLP

20070043058 - Novel 2,3-dihydroindole compounds: v

20070043059 - N-oxides as prodrugs of piperazine and piperidine derivatives:

20070043060 - Oxazole derivatives, preparation and therapeutic use thereof:

20070043063 - Azaindoles useful as inhibitors of jak and other protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Karen Brown Vertex Pharmaceuticals Incorporated

20070043061 - Furazanobenzimidazoles: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is oxygen, a carbonyl group, an oxime derivative of a carbonyl group or an α,β-unsaturated carbonyl group, and the substituents R1 to R6 have the meanings given in the specification, for use as medicaments, to... Agent: Gibbons, Del Deo, Dolan, Griffinger & Vecchione

20070043062 - Isoxazoles as peptide deformylase inhibitors: Isoxazole compounds of formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other disease in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly caused by... Agent: Edwards & Angell, LLP

20070043064 - 7-substituted 3-nitro-pyrazo[1,5-a] pyrimidines: The present invention relates to compounds of Formula (I): wherein R1 is as defined in the claims. The compounds have specific affinity for the GABAA receptor and are therefore useful in the treatment and prevention of diseases modulated by the α1- and α2-GABAA receptors.... Agent: Birch Stewart Kolasch & Birch

20070043065 - Amide derivatives: The invention concerns a compound of the Formula (I) wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or (1-6C)alkyl; and R4 is (3-6C)cycloalkyl; or pharmaceutically-acceptable salts thereof; processes for their... Agent: Morgan Lewis & Bockius LLP

20070043066 - Glutamate aggrecanase inhibitors: The present invention relates to modulators of metalloproteinase activity.... Agent: Wilmerhale/wyeth

20070043067 - 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups: in which the groups are as defined in the description here below and characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups. Said compounds are endowed with potent topoisomerase I inhibiting activity and therefore are useful as... Agent: Nixon & Vanderhye, PC

20070043069 - Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase:

20070043068 - Pyrrolo-pyridine kinase modulators: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.... Agent: Townsend And Townsend And Crew, LLP

20070043072 - Aminopyridine-derivatives as inductible no-synthase inhibitors: e

20070043071 - Further therapeutic use of zolpidem: An imidazo[1,2-a]pyridine-3-acetamide such as zolpidem is useful in the treatment of a condition of the brain which has a lesion and exhibits diaschisis/dormant cells at the contralateral and other sites, more particularly trauma-induced injury, spinocerebellar ataxia, cerebellar or cerebral infarct and Ramsey-Hunt syndrome.... Agent: Rankin, Hill, Porter & Clark, LLP

20070043073 - Imidazopyridine-derivatives as inductible no-synthase inhibitors:

20070043074 - Imidazo[1,2-a] pyridine anxiolytics:

20070043070 - Weak base salts: Pharmaceutical compositions comprising a salt of a weak base compound of formula: wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, methyl, ethyl or oxy-chloro;... Agent: Greenlee Winner And Sullivan P C

20070043075 - 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts: This invention relates to novel (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts, such as L-tartrate monohydrates and anhydrates. The salts are useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these salts in a method for therapy and to pharmaceutical compositions comprising the salts of the invention.... Agent: Birch Stewart Kolasch & Birch

20070043076 - Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis: The present invention is directed to substituted 2-arylmethylene-N-aryl-N′-aryl-malonamides and analogs thereof. The present invention also relates to the discovery that the compounds are activators of caspases and inducers of apoptosis. Therefore, the activators os caspases and inducers of apoptosis of this invention can be used to induce cell death in... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070043077 - Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents: e

20070043078 - Angiogenesis inhibitor: wherein R1, R2, and R3 each independently represent a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group, a halogen-substituted alkyl group, an alkoxy group, an alkylthio group, a carboxyl group, an alkoxycarbonyl group, or an alkanoyl group; W1 and W2 each independently represent N or CH; X... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043079 - Heterocyclic compound containing nitrogen atom and use thereof: wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and/or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or... Agent: Sughrue-265550

20070043080 - Substituted anilinic piperidines as mch selective antagonists: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20070043081 - Novel pyridine derivatives: The invention relates to novel pyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Dickstein Shapiro LLP

20070043082 - Use of antimuscarinic drugs: The use of antimuscarinic drugs, biperiden in special, as a medication for preventing the onset of epilepsy that might ensure after the condition of status epileticus, major head trauma, including those occasioned by neurosurgical trauma, and acute lesional events to the brain.... Agent: Thomas A. O'rourke Bodner & O'rourke, LLP

20070043083 - Thiazolyl piperidine derivatives: wherein R1, R2 and R3 are as defined in the description and claims. It further relates to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070043084 - 1,2-diarylimidazoles useful as inhibitors of cox: A compound of the formula (1): wherein R1 is cyano, and the like; R2 is hydroxy, and the like; R3 is (lower)alkoxy, and the like; X and Y are each CH or N; or pharmaceutically acceptable salts thereof, which are useful as a medicament.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070043085 - Process for the preparation of amorphous form of neutral esomeprazole: A process for preparing neutral esomeprazole in an amorphous form is provided comprising (a) providing an aqueous solution comprising a salt of esomeprazole; (b) neutralizing the solution with a neutralization agent to provide a neutralized solution; (c) contacting the neutralized solution with an extracting solvent; and (d) recovering the neutral... Agent: M. Carmen & Associates, PLLC

20070043086 - Agents for controlling plant pests: p

20070043087 - Compounds exhibiting thrombopoietin receptor agonism: wherein R1 is a hydrogen atom, a halogen atom, or the like; R2, R3, and R4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R5 is a hydrogen atom or the like; R6... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070043088 - Process for preparing lacidipine: A process for preparing lacidipine, comprising reacting a t-butoxy carbonyl methyl aryl phosphonium halide with o-phthalaldehyde, and further reacting a product comprising (E)-3-(2-formylphenyl)-2-propenoic acid, 1,1-dimethyl ethyl ester, without isolation, with ethyl-3-amino crotonate.... Agent: Dr. Reddy's Laboratories, Inc.

20070043089 - Method of inhibiting angiogenesis: p

20070043091 - Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency:

20070043090 - Novel sulfonamides: R4 and R5 are independently selected from the group consisting of H, C1-C10 alkyl, C1-C10 alkyl hydroxyl; m is 0 or an integer from 1 to 3 and n is an integer of from 1 to 4. These compounds are useful in lowering intraocular pressure and/or treating glaucoma or providing... Agent: Allergan, Inc.

20070043092 - Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders: A method of treating angiogenesis-implicated disorders by selecting a subject predisposed to an angiogenesis-implicated disorder and then administering an effective amount of an endogenous aryl hydrocarbon receptor ligand or its analogs according to a formula as disclosed herein is disclosed.... Agent: Quarles & Brady LLP

20070043093 - Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same: The present invention provides the glucagon-like peptide-1 receptor agonists. It is indicated that the agonists have good binding capability to glucagon-like peptide-1 receptor by pharmacological tests. The present invention also provides the preparation of the agonists.... Agent: Baker & Hostetler LLP

20070043094 - Pioglitazone hydrochloride: Provided is a novel crystal form of pioglitazone hydrochloride and a method for making it. Also provided is a method for making a known crystal form of pioglitazone hydrochloride.... Agent: Kenyon & Kenyon LLP

20070043095 - Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use: o

20070043097 - Medicaments containing famotidine and ibuprofen and administration of same: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in admixture, is administered three times per day.... Agent: Townsend And Townsend And Crew, LLP

20070043096 - Unit dose form with ibuprofen-famotidine admixture: An oral dosage form for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in admixture, in amounts suitable for three times per day administration.... Agent: Townsend And Townsend And Crew, LLP

20070043098 - Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides: The present invention relates to a method for preparing substituted tetrazoles, compounds obtained according to this method, new reactants and new tetrazole derivatives.... Agent: Novartis Corporate Intellectual Property

20070043099 - Crystalline forms of carvedilol and processes for their preparation: This invention relates to a novel crystalline form of carvedilol, to processes for its preparation, to compositions containing it and to its use in medicine. This invention further relates to a novel process for preparing crystalline carvedilol Form II.... Agent: Kenyon & Kenyon LLP

20070043100 - Novel polymorphs of azabicyclohexane: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph... Agent: Graybeal, Jackson, Haley LLP

20070043101 - Substituted indoles and methods of their use: The present invention relates generally to substituted indoles and methods of using them.... Agent: Woodcock Washburn LLP

20070043103 - Novel metod for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof: e

20070043102 - Oral suspension of tegaserod: This invention relates to an oral suspension of tegaserod or pharmaceutically acceptable salts thereof. In particular, it relates to an oral suspension comprising a power comprising an effective amount otegaserod or a pharmaceutically acceptable salt thereof in a beverage, e.g. apple juice.... Agent: Novartis Corporate Intellectual Property

20070043104 - Uii-modulating compounds and their use: Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.... Agent: Knobbe Martens Olson & Bear LLP

20070043105 - Preventive for cerebal stroke recurrence: The invention provides a novel cerebral stroke recurrence inhibitor, and relates to a simple evaluation method for an cerebral stroke recurrence inhibitor. According to the simple evaluation method using stroke-prone spontaneously hypertensive (SHR-SP) rats, which has been established by the present inventors, it has been confirmed that atorvastatin is effective... Agent: Sughrue-265550

20070043106 - Alpha-lipoic acid concentrate: A water-free concentrate, consisting of ubichinon Q10, a medium-chained triglyceride or triglyceride mixture, α-lipoic acid and/or its derivative as well as one or more emulgators with HLB value between 9 and 19 permitted according to the foodstuff or drug laws has been described.... Agent: Jacobson Holman PLLC

20070043107 - Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane: w

20070043108 - Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders: The invention is directed to a method of preventing or ameliorating a neuropsychiatric or neurodegenerative disease or disorder in a subject. The method includes administering a composition comprising equol in an amount sufficient to prevent or ameliorate the neuropsychiatric or neurodegenerative disease or disorder. The equol may be a racemic... Agent: Brinks Hofer Gilson & Lione

20070043109 - Slimming cosmetic composition: Cosmetic or dermopharmaceutical compositions containing, in a dermatologically acceptable carrier, at least one diterpene among: cafestol, kahweol and chemical derivatives are useful for slimming treatments including prevent and/or treat cellulite or orange peel and/or to refine contours of the face, skin firming, to reduce the steatomery of the thighs, to... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070043110 - Nontoxic potentiation sensitization of ovarian cancer therapy by supplementary treatment with vitamins: A combination of Vitamin C and a quinone used as a supplemental treatment for an ovarian cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the... Agent: Brouse Mcdowell Lpa

20070043111 - Use of ifenprodril in the treatment of pain: Ifenprodil is useful for the treatment of pain.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070043112 - Use of non-opiates for the potentation of opiates: A non-opioid analgesic is used for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070043113 - Novel compounds: The present invention relates to novel phenylalanine compounds, processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.... Agent: Birch Stewart Kolasch & Birch

20070043114 - Nerve regeneration promoters: (wherein all symbols are shown in the description), a salt thereof or a prodrug thereof. The compound of the present invention is suppresses nerve cell death as a substance for accelerating growth and/or differentiation of stem cells (nerve stem cells, embryonic stem cells, bone marrow cells, etc.), a substance for... Agent: Sughrue-265550

20070043115 - Use of choline to prevent thrombosis associated with total parenteral nutrition: Choline deficiency is a risk factor for the development of thrombosis in patients with intestinal failure that require total parenteral nutrition. There is provided a method of preventing thrombosis, preferably venous thrombosis, comprising administering to a patient receiving TPN a nutrient solution comprising choline. Also provided is a method of... Agent: Mcdermott Will & Emery LLP

20070043116 - Method for preventing and/or treating neurodegenerative diseases: The invention relates to a neurodegenerative disease treating agent for parenteral use, which comprises (2R)-2-propyloctanoic acid or a salt thereof. Since the neurodegenerative disease treating agent of the present invention comprising (2R)-2-propyloctanoic acid or a salt thereof, characterized in that a dosage exceeding about 100 mg per dose is parenterally... Agent: Sughrue-265550

20070043117 - Process for the preparation of chirally pure n-(trans-4-is: The invention relates to N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) in the novel crystalline form “G” and a process for the preparation thereof. A process for the preparation of chirally pure nateglinide by treating a lower alkyl ester thereof with a base to yield an alkali salt and liberating the product from said salt... Agent: The Firm Of Karl F Ross

20070043118 - Method of treating a subject suffering from degenerative disc disease using a nitric oxide synthase inhibitor: The present invention provides a method for treating a vertebrate subject suffering from a degenerative disc disease by administering an inhibitor of nitric oxide synthase (NOS) to the subject in an amount effective to treat the subject.... Agent: Cooper & Dunham, LLP

20070043119 - Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.... Agent: Buchanan Ingersoll And Rooney PC

20070043120 - Therapeutic combination for painful medical conditions: A therapeutic combination comprises a first agent comprising a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof, and a second agent effective in combination therewith to (a) provide enhanced treatment of pain associated with or caused by a medical condition, by comparison with the first agent... Agent: Harness, Dickey, & Pierce, P.l.c

20070043121 - Discovery of novel soluble crystalline anesthetics: The invention discloses compounds derived from propofal which have greater aqueous solubility than propofal and are useful as anesthetic agents. The invention further discloses methods of preparing compounds of the invention. The invention also discloses methods of inducing anesthesia in a subject by administering compounds of the invention to the... Agent: University Of Virginia Patent Foundation

20070043122 - Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders: The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070037734 - Process for the purification of il-18 binding protein: The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid comprising hydrophobic charge-induction chromatography.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070037735 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070037737 - Composition and method for the repair and regeneration of cartilage and other tissues: The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere... Agent: David S. Resnick

20070037736 - Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070037738 - Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions: Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as but not limited to cancer, inflammatory or metabolic diseases. Such conditions are linked to genetically inherited mutations of... Agent: Cermak & Kenealy LLP

20070037740 - Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of alphacalcidol, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple... Agent: Cooper & Dunham, LLP

20070037739 - Compounds useful in coating stents to prevent and treat stenosis and restenosis: At least one bioactive agent is locally delivered to a location where a stent is implanted within a lumen in a patient's body. The bioactive agent includes a: DNA minor groove binder (such as CC-1065 or Duocarmycin); apocynin; RGD peptide (such as RGDfV); stilbene compound (such as resveratrol); camptothecin; des-aspartate... Agent: Preston Gates & Ellis LLP Attn: C. Rachal Winger

20070037747 - Exendin 4 polypeptide fragment: The present invention relates to an Exendin 4 polypeptide fragment, which has hypoglycemic activity, and can be used for the treatment of type II diabetes mellitus. The polypeptide sequence described herein is HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, where X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070037744 - Human cathelicidin antimicrobial peptides: Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.... Agent: Buchanan, Ingersoll & Rooney LLP

20070037750 - Methods for glucagon suppression using modified exendins: Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provided. These methods are are useful... Agent: Arnold & Porter LLP (18528) Attn IPDocketing Dept.

20070037748 - Methods of treating diseases with a vegf antagonist: A method of reducing or preventing hypertension associated with administration of a vascular endothelial growth factor (VEGF) antagonist in a human subjects suffering from a disease or condition treatable with a VEGF antagonist in which is it desirable to reduce or prevent hypertension. The method is particularly useful for treatment... Agent: Regeneron Pharmaceuticals, Inc

20070037741 - Novel compositions and methods for the treatment of immune related disease: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.... Agent: Genentech, Inc.

20070037746 - Novel compounds: The present invention relates to novel coagulation factor FVIIa polypeptides.... Agent: Novo Nordisk, Inc. Patent Department

20070037743 - Novel conotoxin modulating sodium channels: A 26 residue peptide (Am2766) with the sequence CKQAGESCDIFSQNCCVGTCAFICIE-NH2 has been isolated and purified from the venom of the molluscivorous snail, Conus amadis, collected of the southeastern coast of India. Chemical modification and mass spectrometric studies establish that Am2766 has three disulfide bridges. Cterminal amidation has been demonstrated by mass... Agent: Foley And Lardner LLP Suite 500

20070037745 - Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer: A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene... Agent: Agensys C/o Morrison & Foerster LLP

20070037749 - Therapeutic fibrin-derived peptides and uses thereof: The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R1 and R2 are either the same or different, wherein R1 and R2 are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from... Agent: Baker & Botts L.L.P.

20070037742 - Use of follicle stimulating hormone for reduction of spermatozoa chromosomal aberration in males: The present invention relates to the use of a substance having a FSH activity for reducing gamete chromosomal alterations in a male, more specifically in men suffering from spermatozoa aneuploidy.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070037751 - Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite: The present invention relates, in one aspect, to the use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. In another aspect, the present invention relates to the use of a ghrelin-like compound... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070037753 - Inhibitors of cancer cell, t-cell and keratinocyte proliferation: e

20070037752 - Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases: The invention relates to substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further relates to the use of at least one such substance or of a pharmaceutical or cosmetic composition containing at least one such substance for the prophylaxis and therapy of diseases, in particular... Agent: Greenblum & Bernstein, P.L.C

20070037754 - Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human inmmunodeficiency virus (HIV)... Agent: Banner & Witcoff

20070037755 - Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors: A method of prevention or treatment of a cholesterol-associated tumor is provided which comprises administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe (SCH 58235) and/or its phenolic glucuronide, or at least one ezetimibe analog, e.g., SCH 48461 and SCH 58053, to a patient wherein the... Agent: Buchanan, Ingersoll & Rooney PC

20070037756 - Compositions and methods for the prevention and treatment of circulatory conditions: The present invention relates to compositions and the prevention and treatment of circulatory conditions. In one embodiment, the present invention contemplates a compositions comprising anti-platelet aggregating activity. In another embodiment, the present invention contemplates methods to prevent or treat vascular or cardiovascular diseases. In another embodiment, the present invention relates... Agent: Peter G. Carroll Medlen & Carroll, LLP

20070037757 - Compounds: e

20070037758 - Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics: The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4′ of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the... Agent: Fulbright & Jaworski L.L.P.

20070037760 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Pepper Hamilton LLP

20070037761 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Raymond A. Miller Pepper Hamilton LLP

20070037762 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve antiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Raymond A. Miller Pepper Hamilton LLP

20070037769 - Compositions and methods to treat and control tumors by loading antigen presenting cells: The present application is directed to non-coding RNA motifs that are used in conjunction with an antigen or without an antigen to induce, enhance or modulate an immune response that compromises a B cell and a T cell component.... Agent: Catalyst Law Group, Apc

20070037765 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070037767 - Immunostimulatory nucleic acids for the treatment of asthma and allergy: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates... Agent: Wolf Greenfield & Sacks, PC

20070037759 - Mammalian retrotransposable elements: The invention relates to a modified retrotransposable element wherein one or more polyadenylation sites have been removed from within the genes of the retrotransposable element, and methods of use thereof. Sequences of optimized retrotransposable element are provided that have polyadenylation sites removed, and may be further modified to optimize codon... Agent: Howrey LLP

20070037764 - Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells: The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of human immunodeficiency virus-1 (HOV-1), as in treatment of a viral infection. The antisense antiviral compounds have morpholino subunits linked by uncharged phosphorodiamidate linkages interspersed with cationic phosphorodiamidate linkages. An exemplary embodiment of the invention... Agent: Perkins Coie LLP

20070037768 - Methods for therapy of neurodegenerative disease of the brain: A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic... Agent: Foley & Lardner LLP

20070037766 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070037763 - Oligonucleotide compound and method for treating nidovirus infections: A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between... Agent: Perkins Coie LLP

20070037770 - Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3′-NHP(O)(S−)O-5′ linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3′→P5′ phosphoramidates and to exhibit a much higher acid... Agent: Geron Corporation

20070037773 - Methods and compositions for treating flaviviruses and pestiviruses: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.... Agent: King & Spalding LLP

20070037771 - Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates: A process is provided for the preparation of branched-chain ribonucleosides of formula (I) from the 1,2-anhydro derivatives of formula (II). The compounds of formula (I) are inhibitors of HCV polymerase useful in the treatment of HCV infection.... Agent: Merck And Co., Inc

20070037772 - Pyrazolidinol compounds: The invention provides the use of an optionally hydroxyl-protected 4-hydroxy or hydroperoxy-3,5-dioxopyrazolidine or an equivalent wherein a pyrazolidine ring attached oxygen is replaced by a sulphur, or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in drug therapy or prophylaxis. Additionally, the invention provides a... Agent: Bacon & Thomas, PLLC

20070037774 - Novel cytarabine monophosphate prodrugs: e

20070037775 - Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be... Agent: Seed Intellectual Property Law Group PLLC

20070037776 - Polysaccharides for delivery of active agents: Formulation and methods for modulating the delivery of an agent using polysaccharides.... Agent: Fish & Richardson PC

20070037777 - Lipid-containing compositions and methods of using them: Anabolic compositions can be administered to patients with chronic diseases, or who suffer from conditions precipitated by such diseases or long term treatment regimes. The compositions comprise at least one surfactant wherein the total concentration of surfactant in the composition is greater than 1% (w/w or w/v), and can cause... Agent: Ip Group Of Dla Piper US LLP

20070037778 - Substituted phenylsulfonamide inhibitors of beta amyloid production: a

20070037779 - Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof: The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070037780 - Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin... Agent: Thorpe North & Western

20070037781 - Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient: r

20070037782 - Therapeutic agent for ageing macular degeneration:

20070037784 - Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to compounds of formula I which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds... Agent: Merck And Co., Inc

20070037783 - Migrastatin analogs and uses thereof: In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R1—R6, Ra—RC, Q, Y1, Y2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg... Agent: Choate, Hall & Stewart LLP Sloan-kettering Institute For Cancer Research

20070037785 - Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases: The present invention relates to substances capable of specifically inhibiting Gly-Pro-p-nitroanilide cleaving peptidases, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for... Agent: Greenblum & Bernstein, P.L.C

20070037786 - Cephem compounds: e

20070037787 - Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070037788 - Tricyclic steroid hormone nuclear receptor modulators: The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis... Agent: Eli Lilly & Company

20070037789 - Fluoro substituted 2-oxo-azepan derivatives: R3/R3′, R4/R4′ and R5/R5′ are as defined in the specification and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds are γ-secretase inhibitors which can be useful in the treatment of Alzheimer's disease or common cancers including, but not limited to, cervical carcinomas... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070037790 - Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them: Compounds which are pyrrolo-pyrazole derivatives and pharmaceutically acceptable salts thereof, together with the process for their preparation and pharmaceutical compositions thereof are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders,... Agent: Scully, Scott, Murphy & Presser

20070037791 - Pentacyclic kinase inhibitors: m

20070037792 - Pharmaceutical compositions: Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect.... Agent: Novartis Corporate Intellectual Property

20070037793 - Benzylamine analogues: wherein R1 is a C1-C6 alkyl group, an amino group, a (C1-C6 alkyl)amino group, a di(C1-C6 alkyl)amino group or a nitrogen-containing saturated heterocyclic group; R3 is a hydrogen atom or a C1-C6 alkyl group; Arom is an unsubstituted or substituted aryl group or an unsubstituted or substituted heteroaryl group; wherein... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070037794 - Heteroaryl sulfonamides and ccr2: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as... Agent: Brinks Hofer Gilson & Lione

20070037795 - Benzylamine analogues: wherein R1 is a C1-C6 alkyl, an amino, a (C1-C6 alkyl)amino, a di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are the same or different and are a hydrogen or a C1-C6 alkyl; Arom is an unsubstituted or substituted aryl or an unsubstituted or substituted heteroaryl; wherein the... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070037796 - 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b): The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.... Agent: Eli Lilly & Company

20070037797 - Method of reducing the risk of adverse cardiovascular (cv) events associated with the administration of pharmaceutical agents which favor cv events: Methods and compositions for reducing the risks of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which induce or increase the risk of one or more adverse CV events, particularly the non-steroidal anti-inflammatory drugs (NSAIDs) and especially the cyclooxygenase-2 (COX-2) inhibitors, are disclosed. The methods involve the... Agent: Baker & Botts L.L.P.

20070037798 - Thiolactones: This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-β activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy,... Agent: Arnold & Porter LLP (20595) Attn:IPDocketing Dept.

20070037799 - Fungicide ternary active ingredient combinations: The present invention relates to a novel active compound combination which consists of the known 3-{1-[2-(4-<2-chlorophenoxy>-5-fluoropyrimid-6-yloxy)phenyl]-1-(methoximino)methyl}-5,6-dihydro-1,4,2-dioxazine (fluoxastrobin) and of other known active compounds and is highly suitable for controlling phytopathogenic fungi.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070037800 - Method of treating neurological disorders using clotrimazole and derivatives thereof: Methods and pharmaceutical compositions are disclosed for treating neurological disorders, such as Huntington's disease or Alzheimer's disease. The methods involve the administration of a triarylmethane compound, such as clotrimazole, or a salt thereof.... Agent: Edwards & Angell, LLP

20070037803 - Benzimidazole derivatives: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.... Agent: Jones Day

20070037801 - Novel indoles are cannabinoid receptor ligands: m

20070037802 - Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070037805 - Fused heteroaryl derivatives: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.... Agent: Fulbright & Jaworski, LLP

20070037804 - Imidazolone phenylalanine derivatives: and the pharmaceutically acceptable salts thereof wherein the variables A, n, R5, R21—R24 and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070037807 - Pyridine compounds as inhibitors of dipeptidyl peptidase iv: R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent... Agent: Mark Chao Takeda Pharmaceuticals North America Inc

20070037806 - Pyrrolidine derivatives as oxytocin antagonists: The present invention relates to novel pyrrolidine derivatives of Formula (I), its geometrical isomers, its optically active forms as enantiomers, diastercomers, mixtures of these and its racemate forms, as well as salts thereof, wherein: Rlis selected from the group comprising or consisting of H and C1-C6-alkyl; R2 is selected from... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070037808 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20070037809 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070037810 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070037811 - Hiv inhibiting 1,2,4-triazines: The present invention relates to HIV replication inhibitors of formula (I) as defined in the specification their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.... Agent: Philip S. Johnson Johnson & Johnson

20070037812 - Phenoxyether derivatives as ppar modulators: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis,... Agent: Eli Lilly & Company

20070037814 - Acylsulfamide inhibitors of factor viia: Compounds having the general formula I are useful for inhibiting serine protease enzymes, such as Tissue Factor VIIa, factor Xa, thrombin and kallikrein and have improved permeability properties. These compounds may be used in methods of preventing and/or treating clotting disorders.... Agent: Genentech, Inc.

20070037813 - Serine protease inhibitors: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.... Agent: Genentech, Inc.

20070037817 - Acetylenic piperazines as metabotropic glutamate receptor antagonists: m

20070037816 - Bicyclic piperazines as metabotropic glutatmate receptor antagonists:

20070037815 - Novel pharmaceutical compounds: The present invention relates to derivatives of tadalafil, substituted with fluorine on the methylene carbon atom situated between the oxygens of the benzodioxol ring, and optionally further substituted with deuterium atoms in place of normally abundant hydrogen, and 13C in place of normally abundant 12C. These compounds are selective PDE5... Agent: Edwards & Angell, LLP

20070037818 - Discovery of valuable properties for the primary energy source \"pes 2000 plus folic acid\": A. An oral therapeutic dose of “PES 2000 plus Folic Acid”, which contains folic acid, succinic acid, glutamic acid, calcium succinate, B-12, di-calcium phosphate, magnesium stearate, and gelatin. PES 2000 reduces formation of triglycerides, cholesterol, and thru oxidative metabolism excessive build up of apolipoprotein E4 is prevented. This reduction aids... Agent: William H. Livingston, D.v.m. Livingston Research Corporation

20070037819 - 4-[(arylmethyl)aminomethyl]piperidine derivatives, their preparation and their therapeutic application:

20070037820 - Substituted piperazines as metabotropic glutamate receptor antagonists:

20070037822 - Azinone and diazinone v3 inhibitors for depression and stress disorders:

20070037821 - Nitrosated glutamic acid compounds, compositions and methods of use: The invention describes novel nitrosated glutamic acid compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated glutamic acid compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated glutamic... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070037823 - Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators: The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and... Agent: Michael Best & Friedrich, LLP

20070037824 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070037825 - Enhancing the effect of radioimmunotherapy in the treatment of tumors:

20070037826 - Indolylmaleimide derivatives: which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose... Agent: Novartis Corporate Intellectual Property

20070037827 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070037828 - Pyrazolopyrimidines: o

20070037829 - 4-cycloakylaminopyrazolo pyrimidine nmda/nr2b antagonists: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.... Agent: Merck And Co., Inc

20070037830 - 2-adamantyl derivatives as p2x7 receptor antagonists.: The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or solvate or pro-drug thereof, wherein A, B, X, n and m have the meanings as defined in the specification. Processes for their preparation; pharmaceutical compositions containing them; and their use in therapy are also described.... Agent: Fish & Richardson P.C.

20070037831 - Methods of using pde 5 inhibitors for the treatment of congestive heart failure: e

20070037832 - Novel adenine derivatives: wherein X represents NR3 (wherein R3 represents a hydrogen atom or C1-3 alkyl) or the like; R1 represents substituted or unsubstituted alkyl or the like; R2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070037833 - Compositions and methods for inhibiting neurodegeneration: Methods effective for inhibiting neuronal degeneration, particularly in ALS patients are disclosed. Also provided are screening assays for identifying such agents.... Agent: Dann, Dorfman, Herrell & Skillman

20070037834 - Bicyclic pyrimidine derivatives: Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related... Agent: Fitzpatrick Cella Harper & Scinto

20070037835 - Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid: The present invention relates to combinations suitable for the treatment of pain of various genesis or aetiology comprising a cathepsin S inhibitor and an opioid, for simultaneous, separate or sequential use, to a method of treating or ameliorating pain in a warm-blooded animal in need thereof, to the use of... Agent: Novartis Corporate Intellectual Property

20070037836 - Mch receptor antagonists: The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.... Agent: Sughrue Mion, PLLC

20070037837 - Quinazoline derivatives: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, R2, X1, R5 and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in... Agent: Morgan Lewis & Bockius LLP

20070037838 - Substance which exhibits antiviral and antibacterial activity and is based on derivatives of 2,8-dithioxo-1h-pyrano[2,3d 6,5-d']dipyrimidyne and 10-aza-analogue thereof: The invention relates to organic chemistry and medicine, more specifically to synthetic pyrimidine derivatives, i.e. 2,8-dithioxo-1H-pyrano[2,3d,6,5-d′]dipyrimidyne and 10-aza-analogue thereof and to the complexes and salts thereof which exhibit antiviral and antimicrobial activity. Said invention can be used for medicine and veterinary science for treating viral diseases, bacteria-induced diseases and for... Agent: Patent, Copyright & Trademark Law Group

20070037839 - 2-anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk(cdk2) inhibitors: Compounds of the formula (I), and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are desc ribed. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.... Agent: Morgan Lewis & Bockius LLP

20070037840 - Tricyclic benzimidazoles: m

20070037841 - Inhibitors: An inhibitor contains naphthyridine dimer, a naphthyridine-azaquinolone hybrid, a trinaphthyridine-azaquinolone hybrid, or a trinaphthyridine-azaquinolone hybrid derivative. In order to inhibit binding of 100 nM of RRE to 100 nM of Rev protein, for example, an inhibitor containing naphthyridine dimer is used at a molarity of 1.2 μM to 12 μM,... Agent: Sheridan Ross PC

20070037842 - Polymorphs and amorphous form of (s)-(+)-clopidogrel bisulfate: The present invention relates to new polymorphs of S-(+)-Clopidogrel bisulfate and a process for preparing the same.... Agent: Nixon & Vanderhye, PC

20070037843 - Zolpidem hemitartrate: The present invention provides for novel polymorphs of zolpidem hemitartrate and the preparation of the polymorphs.... Agent: Kenyon & Kenyon LLP

20070037844 - Amides of acetic and propionic acids: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.... Agent: Jeffrey M. Greenman

20070037845 - Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors, and intermediates thereof: e

20070037847 - Drugs for spinal anesthesia: Spinal anesthetics for intrathecal administration to produce spinal anesthesia are provided with use of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue or its pharmaceutically active analogs.... Agent: Mckee, Voorhees & Sease, P.L.C

20070037846 - Pyrazolidinedione derivatives: The present invention relates to compounds of alkylidene pyrazolidinedione derivatives, which are effective platelet ADP receptor antagonists that prevent platelet aggregation and thrombosis. Thus, the present invention also relates to pharmaceutical compositions that contain the compounds as well as methods of preventing or treating peripheral, visceral, hepatic, renal, cardio- and... Agent: Dickstein Shapiro LLP

20070037848 - Treatment of neurological conditions: The present invention relates generally to the treatment of conditions and/or disorders associated with or exacerbated by oxidative stress and which have symptoms including cognitive impairment such as pre- or mild cognitive impairment or memory loss. The agents and methods useful for the practice of the present invention are proposed... Agent: Scully, Scott, Murphy & Presser

20070037849 - Urea derivative and process for producing the same: e

20070037850 - Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives: a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 and R2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl; R3 is hydrogen or halo; R4 is... Agent: Philip S. Johnson Johnson & Johnson

20070037851 - 4,4-disubstituted) piperidine derivatives having ccr3 antagonism: The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions... Agent: Sughrue Mion, PLLC

20070037852 - Migrastatin analogs and uses thereof: The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1—R6, Ra—Rc, Q, Y1, Y2 and n are as defined herein.... Agent: Patent Deparment Choate, Hall & Stewart LLP

20070037853 - Substituted imidazole compounds as ksp inhibitors: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds. The compounds of the invention have the following general formula:... Agent: Novartis Vaccines And Diagnostics Inc.

20070037854 - Process for preparing sulfonamide-containing indole compounds: e

20070037855 - Compounds for inhibiting beta-amyloid production and methods of identifying the compounds: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or... Agent: King & Spalding LLP

20070037856 - Pyrrole-type compounds, compositions and methods for treating cancer or viral disease: The present invention relates to novel Pyrrole-Type compounds, compositions comprising Pyrrole-Type compounds, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a composition comprising a Pyrrole-Type compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070037857 - Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070037858 - Hexyl carboxanilides and their use for controlling undesirable micro-organisms: e

20070037859 - Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use: (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I herein; and/or (v) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in FIG. IV herein; a process for the preparation of such a compound, a pharmaceutical composition containing... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070037860 - Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy: The combination of amlodipine with atorvastatin metabolite shows a synergistic antioxidant effect on lipid peroxidation in human low-density lipoproteins and membrane vesicles enriched with polyunsaturated fatty acids. Inhibition of oxy-radical damage by this drug combination was observed at therapeutic levels in a manner that could not be reproduced by the... Agent: Burns & Levinson, LLP (formerly Perkins Smith & Cohen LLP)

20070037861 - Enhanced method of treatment of growth disorders: The application relates to the treatment of conditions and diseases for which growth hormone is a desirable method of treatment, using free fatty acid regulators in combination with growth hormone. In particular, the present invention discloses an enhanced method of treatment of growth disorders as well as methods to prevent... Agent: Pharmacia Corporation Global Patent Department

20070037863 - Dipeptide phenyl ethers: Novel dipeptide ethers are effective for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels. The dipeptide ethers are also useful for the treatment and/or prophylaxis of diabetes, obesity, inflammation and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.... Agent: Beyer Weaver & Thomas, LLP

20070037864 - Intermediates for the preparation of lipoxin a4 analogs: v

20070037862 - Thiazolidinones, their production and use as pharmaceutical agents:

20070037865 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070037866 - Treating agent for irritable bowel syndrome: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as... Agent: Edwards & Angell, LLP

20070037867 - Antihepatitis c virus agent and anti-hiv agent: An anti-hepatitis C virus agent or anti-HIV agent comprising, as an active ingredient, a fullerene derivative which has a nitrogen atom forming a ring together with adjacent bonded carbon atom pairs constituting the carbon cluster skeleton of the fullerene or a quaternary amine salt thereof is provided.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070037868 - Macrocyclic diaminopropanes as beta-secretase inhibitors: wherein R1, R2, R4, R5, n, L, Z, and as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the... Agent: Louis J. Wille Bristol-myers Squibb Company

20070037869 - Histone deacetylase inhibitors: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition... Agent: Steptoe & Johnson LLP

20070037870 - Novel substance having alpha-glucosidase inhibiting activity and food containing the same: To provide a novel substance having α-glucosidase inhibiting activity, derived from natural products and being safe, which substance has not only a blood sugar ameliorating activity being effective in the prevention or treatment of diabetes or obesity but also an activity of reducing postprandial hyper-blood sugar, etc. and to provide... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070037871 - Pkc activation as a means for enhancing sappalpha secretion and improving cognition using bryostatin type compounds: The present invention relates to compositions and methods to modulate α-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070037872 - Inducing peripheral blood vesel vasodilation: The invention relates to compositions, and methods of use thereof, containing polyphenols such as flavanols, procyanidins, their derivatives and epimers thereof, for inducing peripheral blood vessel vasodilation, for example for treating or preventing peripheral vascular diseases.... Agent: Nada Jain, P.C.

20070037873 - Airway remodeling treatments: Described are new uses for ajulemic acid and derivatives of ajulemic acid to treat airway remodeling.... Agent: Fish & Richardson PC

20070037875 - Genistein inhibition of transthyretin amyloidosis: Genistein is an excellent transthyretin amyloidogenesis inhibitor and exhibits excellent binding selectivity in plasma. Treatment of patients having transthyretin amyloidosis with therapeutic agents containing genistein is disclosed to ameliorate the disease condition.... Agent: The Scripps Research Institute

20070037874 - Manufacturing process of isoflavan or isoflavene derivatives: The present invention relates to a method of synthesizing isoflavan and isoflavene derivatives of the Formula 1, which have the biological efficacy of antioxidation and protection against ultraviolet light. The method is effective and suitable for a mass production of isoflavan and isoflavene derivatives, which is a more convenient alternative... Agent: Jhk Law

20070037876 - Benzopyrone compounds, preparation method and use thereof: The present invention, having good pesticide activity and broad bactericide activity, applied for controlling various pests in plants such as army worm, diamond backmoth and aphid, carmine spider mite, two-spotted spider mite, ladybeetle, mites and mosquito larvae. Various disease in plants can be controlled by the invention and that of... Agent: Smith, Gambrell & Russell

20070037877 - Novel coumarin derivatives as ion channel openers: The present invention is directed to novel coumarin derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels... Agent: Philip S. Johnson Johnson & Johnson

20070037878 - Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease: The present invention is generally related to the discovery of the therapeutic benefit of administering γ-tocopherol and γ-tocopherol derivatives. More specifically, the use of γ-tocopherol and racemic LLU-α, (S)-LLU-α, or γ-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer,... Agent: Knobbe Martens Olson & Bear LLP

20070037879 - Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease: The present invention is generally related to the discovery of the therapeutic benefit of administering γ-tocopherol and γ-tocopherol derivatives. More specifically, the use of γ-tocopherol and racemic LLU-α, (S)-LLU-α, or γ-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer,... Agent: Knobbe Martens Olson & Bear LLP

20070037880 - Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrances: The present invention is directed to compositions containing ascorbic acid or a physiologically acceptable salt thereof for the preparation of a formulation useful for the prevention of fungal infection recurrences or fungal superinfections in patients at risk.... Agent: Nixon & Vanderhye, PC

20070037881 - Amidoacetonitrile derivatives: wherein either R signifies C1-C6-alkyl, halo-C1-C6-alkyl,C1-C6-alkoxy-C1-C6-alkyl or halo C1-C6-alkoxy-halo-C2-C6-alkyl, and X1 signifies a single bond, O, S, S(O) or S(O)2; or R signifies halogen and X1 signifies a single bond; X2 signifies CN, halogen, C1-C6-alkyl, halo-C1-C6-alkyl, C1-C6-alkoxy, halo-C1-C6-alkoxy, C1-C6-alkoxycarbonyl, C1-C6-alkyl, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-alkylsulfonylamino, halo-C1-C6-alkylsulfonylamino, OH, NH2, COOH, CONH2, C1-C6-alkylaminocarbonyl or... Agent: Novartis Corporate Intellectual Property

20070037882 - Remedy for cerebral neurodegenerative diseases using ppar agonist: In accordance with the invention, a compound with a protective action for nerve cell can be reselected by adding PPARδ agonist to a culture cell system where toxic substances such as thapsigargin, MPP+ and staurosporine are preliminarily allowed to react and reselecting a compound improving the survival rate. The compound... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070037883 - Therapeutic compositions: The present invention provides compounds, compositions and methods for inhibiting or reducing reactive oxygen species (ROS) production in cells, such as in cells of the vascular system and in particular the smooth muscle-containing vasculature and/or endothelial cell-containing vasculature and/or adventitial fibroblast-containing vasculature. ROS production may also be inhibited in non-vascular... Agent: Jennifer M Mccallum, Ph D, Esq The Mccallum Law Firm, LLC

20070037884 - Novel succinate salt of o-desmethyl-venlafaxine: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.... Agent: Wyeth Patent Law Group

20070037885 - Biomass containing animal feed: We describe a method to increase the viability, weight, development and behaviour of animals comprising administering to a pregnant animal a long chain fatty acid such as docosahexaenoic acid.... Agent: Klarquist Sparkman, LLP

20070037886 - Bone marrow erythroid progenitor cell(s) differentiation inducer: Bone marrow erythroid progenitor cell(s) differentiation may be induced and anemia may be treated by administering arginine. Arginine is an excellent differentiation inducer, because it has high safety, can be orally administered, and is widely used.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070037887 - Blockade of mtor to prevent a hormonal adaptive response: One embodiment of the present invention is directed to the use of an mTOR inhibitor, such as farnesylthiosalicylic acid (FTS), to prevent a hormonal adaptive response during hormonal deprivation treatment of a hormonal responsive cancer.... Agent: University Of Virginia Patent Foundation

20070037888 - 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer: A compound of Formula (I); wherein the substituents are as defined in the text for use in modulating insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.... Agent: Astrazeneca R&d Boston

20070037889 - Anticancer composition comprising obovatol or obovatal: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and... Agent: Medlen & Carroll, LLP

20070037890 - Cannabinoids: s

20070037891 - Methods and compositions for the delivery of biologically active agents: The invention features polymers noncovalently complexed with a biologically active agent. The polymer complexes include at least one shielding moiety covalently tethered to at least one complexing moiety, which is complexed with at least one biologically active agent.... Agent: Clark & Elbing LLP

20070032403 - Crystal structure of the itk kinase domain: Disclosed are polypeptides encoding the ITK kinase domain and nucleic acids encoding such polypeptides, crystal structures of various polypeptide-ligand complexes comprising the ITK kinase domain bound to a ligand, methods of producing the aforementioned polypeptides and nucleic acids which encode them and methods of producing crystal structures of the aforementioned... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070032404 - Methods for treating diabetes and related disorders using pde10a inhibitors: The methods of the invention relate to the treatment of diabetes, including type 2 diabetes, and related disorders by administration of a PDE10A inhibitor. Such PDE10A inhibitors may be administered in conjunction with alpha-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, B-3 agonist, or insulin. Such PDE10A... Agent: Jeffrey M. Greenman

20070032405 - Branched water-soluble polymers and their conjugates: The present invention provides branched water-soluble polymers that allow two or more water-soluble polymers to be conjugated to another species. The branched polymers provide access to therapeutic agents that are conjugated at a single site to two or more water-soluble polymers. The branched polymers are based upon branch points that... Agent: Morgan, Lewis & Bockius LLP (sf)

20070032406 - Identification of novel nogo-receptors and methods related thereto: Disclosed are compositions relating to the Nogo receptor (NgR) family as well as fragments, chimeras, and variants thereof. The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the NgRs as well as uses thereof. Such uses include modulation neurite outgrowth in a subject... Agent: Needle & Rosenberg, P.C.

20070032407 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070032409 - Bradykinin receptor antagonists and uses thereof: The present invention regards bradykinin receptor antagonists for treatment of a medical condition. In particular, the medical condition follows cardiopulmonary bypass. In specific embodiments, bradykinin receptor antagonists are used for the treatment of protamine-induced hypotension and/or fibrinolysis.... Agent: Fulbright & Jaworski, LLP

20070032410 - Compositions and methods for the treatment of psychiatric disorders: Methods and compositions containing oxytocin or an oxytocin analog, specifically carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of the invention are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety,... Agent: Nastech Pharmaceutical Company Inc

20070032408 - Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds: t

20070032411 - Protein kinase signalling: The present invention provides a method of selecting or designing a compound for the ability to regulate JAK activity. The method comprises assessing the ability of the compound to modulate the interaction of the pseudo-substrate loop (PSL) with the kinase like domain (KLD) of JAK. In addition the present invention... Agent: Morrison & Foerster LLP

20070032412 - Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis: Kahalalide compounds, in particular kahalalide F, are of use in a method to treat a mammal suffering from skin disease with avoiding toxicity and leading to clinical improvement.... Agent: King & Spalding

20070032416 - Chorionic somatomammotropin hormone splice variants: This invention relates to novel proteins, termed INSP100 and INSP104, herein identified as novel splice variants of human Chorionic somatomammotropin hormone 2 (hCS-B; Q14407) and human Chorionic somatomammotropin hormone 1 (hCS-A; P01243) respectively and to the use of these proteins and nucleic acid sequences from the encoding genes in the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070032425 - Compositions for diabetes treatment and prophylaxis: Gurmarin containing compositions are useful for modulation of glucose metabolism and the treatment of diabetes. Glucose metabolism in a human patient is regulated by isolated gurmarin-containing dosage forms that contain optionally a non-metabolizable polysaccharide such as the exudate of Sterculia urens.... Agent: Olson & Hierl, Ltd.

20070032415 - Compositions, splice variants and methods relating to breast specific genes and proteins: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of... Agent: Licata & Tyrrell P.C.

20070032419 - Fusion polypeptides, and use thereof in antivascular tumor therapy: The present invention relates to fusion polypeptides, comprising at least two peptides. The invention further relates to the use of these fusion proteins in antivascular therapy of neoplastic diseases and to their use I the production of a drug for the treatment of neoplastic diseases.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070032413 - Human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors,... Agent: Human Genome Sciences Inc Intellectual Property Dept.

20070032414 - Human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cardiovascular diseases, disorders, and/or conditions related thereto. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells and... Agent: Human Genome Sciences Inc Intellectual Property Dept.

20070032423 - Methods and compositions for modulating somatolactogenic functions: Compositions containing cyclophilin B, mutants of cyclophilin B or inhibitors of cyclophilin B and methods of using these compositions to modulate somatolactogenic function are provided.... Agent: Licata & Tyrrell P.C.

20070032427 - Methods and compositions for preserving the viability of photoreceptor cells: Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous calcineurin or constitutively active calcineurin, inhibiting cleavage of calcineurin to constitutively active calcineurin, and/or... Agent: Goodwin Procter LLP Patent Administrator

20070032421 - Methods and compositions relating to cystatin c: A method of treating amyloidoses by administering an effective amount of a cystatin C composition. A method of preventing and inhibiting Aβ oligomerization by administering an effective amount of a cystatin C composition. A composition for inhibiting Aβ oligomerization including an effective amount of a cystatin C composition. A method... Agent: Kenneth I. Kohn Kohn & Associates, PLLC

20070032429 - Methods of using retro-inverso peptides derived from interleukin-6: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the... Agent: Kenyon & Kenyon LLP

20070032422 - Methods, compositions and articles of manufacture for contributing to the treatment of cancers: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.... Agent: Preston Gates & Ellis LLP

20070032428 - Novel antimicrobial agents: A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms,... Agent: Martin D. Moynihan Prtsi, Inc.

20070032417 - Peptides and therapeutic uses thereof: Conformationally constrained peptides that mimic BH3-only proteins, compositions containing them and their use in the regulation of cell death are disclosed. The conformationally constrained peptides are capable of binding to and neutralising pro-survival Bcl-2 proteins. Processes for preparing the conformationally constrained peptides and their use in the treatment and/or prophylaxis... Agent: Heller Ehrman White & Mcauliffe LLP

20070032418 - Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same: Lead compounds were obtained in a high throughput screen (HTS) of angiogenin (ANG; a potent inducer of angiogenesis) enzyme activity, an RNase. One lead was shown to delay appearance of tumors in an animal tumor system, and to reduce the number of animals having tumors. Several lead compound analogs were... Agent: Fulbright & Jaworski L.L.P.

20070032424 - Stimulators of factor x activated (fxa) as new topical antihemorrhagic agents: The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis.... Agent: Moore & Van Allen PLLC

20070032426 - Therapeutic and diagnostic methods for ulcerative colitis and associated disorders: This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20070032420 - Treating diabetes with glucagon-like peptide-1 secretagogues: In general this invention can be viewed as encompassing novel methods of treating diabetes and insulin resistance. The inventors have made the discovery that increasing secretion of endogenous glucagon-like peptide-1 (GLP-1) in combination with inhibiting the activity of dipeptidyl peptidase I (DPP-IV) can have a significant impact on hyperglycemia and... Agent: Entelos, Inc. C/o Foley & Lardner LLP

20070032430 - Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable... Agent: Quine Intellectual Property Law Group, P.C.

20070032431 - Antimicrobial peptides and utilization of the same: Antimicrobial peptide provided by present invention is an artificially designed antimicrobial peptide that does not occur naturally, and includes a sequence composed of at least 6 contiguous amino acid residues selected from an amino acid sequence constituting laminin binding site (LBS), or said sequence with one or a plurality of... Agent: Amin, Turocy & Calvin, LLP

20070032432 - Oligopeptide antagonist of interleukin-6: The present invention provides an antagonist peptide of interleukin-6 (IL-6), wherein the peptide comprises a amino acid sequence which is selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7. The peptide of the invention is able to specifically bind IL-6R... Agent: Birch Stewart Kolasch & Birch

20070032434 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070032433 - Novel peptides as ns3-serine protease inhibitors of hepatitis c virus: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070032435 - Pharmaceutical formulations: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.... Agent: Robert Deberardine Abbott Laboratories

20070032436 - Pharmaceutical formulations: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.... Agent: Robert Deberardine Abbott Laboratories

20070032437 - Iap binding compounds: Compounds that bind cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, IIid. Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these compounds for therapeutic, diagnostic and... Agent: Pepper Hamilton LLP

20070032438 - Pharmaceutical compositions containing taxanes and methods for preparing the pharmaceutical compositions: Pharmaceutical compositions containing taxanes having about 5 to about 75% phospholipid, about 0.01 to about 50% of a surfactant of an HLB value greater than 10, about 0.01 to about 50% alcohol and about 0.01 to about 40% taxane(s) or a derivative thereof.... Agent: Bacon & Thomas, PLLC

20070032445 - Antisense iap nucleobase oligomers and uses thereof: The present invention features nucleobase oligomers that hybridize to IAP polynuclotides, and methods for using them to enhance apoptosis and treat proliferative diseases.... Agent: Philip Swain Phd C/o Gowling Lafleur Henderson

20070032446 - Gapped 2' modified oligonucleotides: Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the... Agent: Woodcock Washburn LLP

20070032444 - Genetic immunization with nonstructural proteins of hepatitis c virus: Nucleic acid molecule that comprise a hepatitis C nonstructural protein including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising a hepatitis C nonstructural protein including a nucleotide sequence encoding NS3, NS4, or NS5, or a combination thereof, operably linked to regulatory elements functional in... Agent: Woodcock Washburn LLP

20070032440 - Oligonucleotides directed against a survivin gene and use thereof: The present invention relates to oligonucleotides directed against a survivin gene and variants thereof and to the use of said oligonucleotides in the diagnosis, prophylaxis, reduction and follow-up of diseases associated with cell growth, differentiation and/or division, such as tumor diseases.... Agent: Norris, Mclaughlin & Marcus, P.A.

20070032447 - Production of reprogrammed cells with restored potential: A method for treating cells and/or nuclear transfer units and/or stem cells in culture with such compounds, individually or in combinations, is described. The method results in a globally hypomethylated genome and a restoration of cell differentiation and/or developmental potential, or potentiality. In addition, a method for the in vitro... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20070032441 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, cosmetic, cosmeceutical, prophylactic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA),... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070032439 - Tarp promoter and uses thereof: A method of providing expression of a molecule in a prostate cell, prostate cancer cell or breast cancer cell comprises introducing into the cell a TARP promoter or a transcriptionally active fragment thereof, operatively linked to a heterologous polynucleotide that codes for the molecule, under conditions effective to direct expression... Agent: Dinsmore & Shohl, LLP

20070032443 - Therapy for alzheimer's disease: The present invention relates to newly identified methods and compositions for modulating the cellular processing of beta-amyloid precursor protein (“APP”) and for the prevention or treatment of diseases associated with abnormal APP processing, such as Alzheimer's disease (“AD”). The invention also relates the identification of molecular pathways heretofore unknown to... Agent: Medlen & Carroll, LLP

20070032442 - Vector utilizing ribonuclease reductase utr and use for inhibiting neoplastic cells: The present invention relates to oligonucleotides having the sequence of an untranslated region (UTR) of mRNA from a housekeeping gene and which can modulate the tumorigenicity of neoplastic cells. The present invention further provides pharmaceutical compositions and methods of inhibiting the growth of neoplastic/malignant cells in a mammal with oligonucleotides... Agent: Viviana Amzel, Ph.d. Nath & Associates PLLC

20070032449 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070032450 - New compositions and methods for the treatment of inflammation: The present invention describes combinations of A2A adenosine receptor agonists and anti-inflammatory compounds for the inhibition of an inflammatory response in mammalian tissue.... Agent: Proskauer Rose LLP

20070032448 - Sugar modified nucleosides as viral replication inhibitors: Various 2′-modified nucleoside analogs and corresponding prodrugs are provided, and particularly contemplated methods of use include use as antiviral agents, and especially as antiviral agents against HCV.... Agent: Thelen Reid Brown Raysman & Steiner LLP

20070032451 - Blood soluble drag reducing hyaluronic acid: The use of hyaluronic acid and physiologically acceptable salts thereof as drag reducing agents is described. The compositions of the invention can be used to increase aortic blood flow, increase arterial blood flow, increase venous blood flow, decrease blood pressure, decrease peripheral vascular resistance, diminish the development of atherosclerosis, and/or... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070032452 - Blood soluble drag reducing hyaluronic acid: The use of hyaluronic acid and physiologically acceptable salts thereof as drag reducing agents is described. The compositions of the invention can be used to increase aortic blood flow, increase arterial blood flow, increase venous blood flow, decrease blood pressure, decrease peripheral vascular resistance, diminish the development of atherosclerosis, and/or... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070032453 - Adjuvant chemotherapy for anaplastic gliomas: The present invention involves the use of nitrone free radical trapping agents in the treatment and prevention of gliomas. The agents may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.... Agent: Fulbright & Jaworski L.L.P.

20070032454 - Silsesquioxane derivative and production process for the same: The present inventors have obtained a PSQ derivative of a completely condensed type into which a functional group is readily introduced by using a novel PSQ derivative of an incompletely condensed type in which four alkaline metal atoms are bonded to silsesquioxane of a cage type having eight Si's. The... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070032455 - Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents: The present invention relates to a novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumours, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzymeprodrug therapy (ADEPT), in conjunction with nitroreductase... Agent: Nixon & Vanderhye, PC

20070032456 - Modulation of cell death: A method of modulating cell death includes administering pyridoxal-5′phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.... Agent: Merchant & Gould PC

20070032457 - Combination therapy for cancer treatment: The present invention provides methods of treating cancer, the methods generally involving combination therapy. The methods are useful as primary cancer therapy, or as adjuvant therapy. The present invention further provides diagnostic methods for determining the responsiveness of a given tumor to treatment with a combination therapy.... Agent: Knobbe Martens Olson & Bear LLP

20070032458 - Compound having activity for inhibiting dioxin toxicity, pharmaceutical composition comprising the compound and method for treating disease resulting from dioxin toxicity using the compound: where, R1 may be a hydrogen atom, a C1-C5 alkyl group or an alkylketone group; and R2 may be a hydrogen atom, a C1-C10 alkyl group or —COR3, wherein R3 may be a C1-C5 alkyl group, a C1-C5 alkylamide group, a C3-C12 aryl group or a heteroaryl group. A compound... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070032459 - Methods of treating conditions associated with an edg-3 receptor: In one aspect, the present invention provides a method of modulating an Edg-3 receptor mediated biological activity in a cell. A cell expressing the Edg-3 receptor is contacted with a modulator of the Edg-3 receptor sufficient to modulate the Edg-3 receptor mediated biological activity. In another aspect, the present invention... Agent: Morgan, Lewis & Bockius LLP (sf)

20070032460 - Use of voacamine and related compounds in the treatment of malaria: Voacamine, voacamine isomers, metabolites and derivatives, and related compounds can be used to, in effect, reverse multi-drug resistance in malaria and are non-toxic. The compounds can be used in combination with known drugs such as chloroquine, arthemesin and qinghaosu to prevent or treat malaria.... Agent: George A. Seaby Seaby & Associates

20070032461 - 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof: The invention provides 1,3 acylated, 24-keto vitamin D3 compounds of formula I: wherein: X1 and X1 are each independently H2 or ═CH2, provided X1 and X1 are not both ═CH2; R1 and R2 are each independently, hydroxyl, OC(O)C1-C4 alkyl, OC(O)hydroxyalkyl, OC(O)haloalkyl, provided that R1 and R2 are not both hydroxyl;... Agent: Edwards & Angell, LLP

20070032463 - Drug, foods or drinks for ameliorating hyperglycemia: A compound having a hyperglycemia improving effect and a hemoglobin Alc lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.... Agent: Knobbe Martens Olson & Bear LLP

20070032464 - Methods of treating cancers: This invention relates to methods for treating cancers.... Agent: Fish & Richardson PC

20070032462 - Novel methods for the preparation of dhea derivatives: The invention relates to a method for the production of DHEA derivatives, such as 7-oxo-DHEA and 7-hydroxy-DHEA, from DHEA itself.... Agent: Alston & Bird LLP

20070032465 - Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha: The invention provides a pharmaceutical product or kit comprising a first active ingredient which is a P2X7 receptor antagonist which P2X7 receptor antagonist is an adamantyl derivative and a second active ingredient which is a tumour necrosis factor α (TNFα) inhibitor, for use in the treatment of inflammatory disorders.... Agent: Fish & Richardson P.C.

20070032466 - Drug containing chymase inhibitor as the active ingredient: The present invention provides drugs containing chymase inhibitors as active ingredients for improving glucose intolerance or preventing and/or treating diseases caused by glucose intolerance. The diseases caused by glucose intolerance are diabetes and/or diabetes complications, wherein the diabetes complications include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinism, insulin resistance... Agent: Sughrue Mion, PLLC

20070032467 - Method for treating hyperlipidemia: Provided is a method for treating hyperlipidemia or hypercholesterolemia, which comprises administering effective doses of ezetimibe and pitavastatin or a salt or lactone derivative thereof.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070032468 - Novel thioxanthine derivatives for use as inhibitors of mpo: wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070032469 - Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070032470 - Novel phenylcarboxyamides as beta-secretase inhibitors: or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and Y as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure... Agent: Louis J. Wille Bristol-myers Squibb Company

20070032471 - Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator: The present invention relates to an active substance combination comprising at least one 2,5-dihydroxybenzenesulfonic compound and at least one K+ channel modulator, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070032472 - Novel process for the preparation of linezolid and related compounds: The present invention provides a novel process for preparation of 5-aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials including linezolid. Thus linezolid is prepared by a) reacting 3-fluoro-4-morpholinyl aniline with R-epichlorohydrin; b) subjecting N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline produced above to carbonylation; c) reacting (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone produced above with potassium phthalinide; d) reacting (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070032473 - Substituted amides and their use as medicaments: e

20070032475 - Novel compounds useful for bradykinin b1 receptor antagonism: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor.... Agent: Elan Pharmaceuticals/finnegan, Henderson Farabow, Garrett & Dunner, LLP

20070032474 - Use of a compound of formula 1 for making a pharmaceutical composition: The invention relates to a compound of formula I or pharmaceutically acceptable salts thereof. The invention further relates to methods of use of this compound.... Agent: Mayer & Williams PC

20070032476 - Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof: and to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (cancers and precancers, dermatological, rheumatic and ophthalmological complaints in particular) or in cosmetic compositions. The invention also relates to a pharmaceutical or cosmetic composition, characterized in that it... Agent: Buchanan, Ingersoll & Rooney PC

20070032478 - Kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent: Robert J. Baran (t2-7h) Allergan, Inc.

20070032477 - Pteridine derivatives useful for making pharmaceutical compositions: This invention relates to a group of substituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydro-derivatives, and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of... Agent: Clark & Elbing LLP

20070032479 - Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines: Compounds according to formula (I) wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered at low dosage for the prevention or treatment of inflammatory disorders, particularly those affecting epithelial tissues such as those of the skin and gastrointestinal tract.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070032480 - Treatment of ischemia-induced arrhythmias: New methods and compositions are provided for preventing development of arrhythmias associated with ischemia and repurfusion. Preferred methods of the invention include treatment to inhibit the mitcohondrial inner membrane anion channel.... Agent: Edwards Angell Palmer & Dodge LLP

20070032481 - Pyrimidine compounds as serotonin receptor modulators: Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20070032482 - Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments: The present invention relates to benzoxazinone-derived sulphonamide compounds of general formula (I), a process for their preparation, a medicament comprising these compounds and the use of benzoxazinone-derived sulphonamide compounds for the preparation of medicaments for 5-HT6 receptor regulation as well as for the treatment of disorders related thereto.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070032484 - Cathepsin k inhibitors: e

20070032483 - Process for the production of mycophenolate mofetil: The present invention relates to a new and economically attractive process for the production of mycophenolate mofetil in a high degree of pharmaceutically acceptable purity, which comprises the reaction of a reactive derivative of mycophenolic acid with 4-(2-hydroxyethyl)morpholine under acidic reaction conditions and the subsequent extraction of the pure mycophenolate... Agent: Novartis Corporate Intellectual Property

20070032485 - Tetrahydronaphthyridine derivatives and a process for preparing the same: wherein R1 is alkoxycarbonyl or the like, R2 is alkyl or the like; R3 is hydrogen or the like; R4 is alkylene or the like; R5 is optionally substituted heterocyclic group; R6, R7, and R8 are independently hydrogen; alky, alkoxy, or the like; R10 is optionally substituted aromatic ring, or... Agent: Birch Stewart Kolasch & Birch

20070032486 - 5ht4-antagonistic 4-(aminomethyl)-piperidine benzamides: The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds.... Agent: Philip S. Johnson Johnson & Johnson

20070032488 - 6-membered aryl and heteroaryl derivatives for treating viruses: Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.... Agent: Foley & Lardner LLP

20070032487 - Inhibitors of phosphatidylinositol 3-kinase: s

20070032489 - Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp): wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070032491 - Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration: The present invention relates to a pharmaceutical formulation comprising a compound which is active as an antagonist of the strychnine-insensitive glycine modulatory site of the N-methyl-D-asparate (NMDA) receptor in combination with a tachykinin NK-1 receptor antagonist, for use in the treatment of neurodegeneration arising, in particular, from stroke or cerebral... Agent: Merck And Co., Inc

20070032492 - Cytokine inhibitors: Where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070032490 - N-phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents: The use of fungicidal compounds of formula Ij wherein A and A′ are both N or A and A′ are both CH or A is CH and A′ is N; j is 0 or 1 and the R groups are as defined in claim 1; their preparation and compositions 10... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070032493 - Method for treating b cell regulated autoimmune disorders: The invention relates to a method for treating B-cell regulated autoimmune disorders using compounds that modulate the activity of c-Rel.... Agent: Edwards & Angell, LLP

20070032494 - Thyroid hormone analogs: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070032495 - Pyrazolotriazines as kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070032496 - Compounds for the treatment of neurodegeneration and stroke: Compounds and related methods for synthesis, and the use of compounds for the treatment of neurodegenerative diseases are disclosed. Compounds are disclosed in connection with PARG and/or PARP inhibition. Therapeutic applications are relevant for preventing or inhibiting neurological cell death for a variety of neurodegenerative conditions including Parkinson's disease, ischemia,... Agent: Greenlee Winner And Sullivan P C

20070032497 - Fused-ring compounds and use thereof as drugs: wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a... Agent: Leydig Voit & Mayer, Ltd

20070032499 - Novel cysteine protease inhibitors and their therapeutic applications: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.... Agent: Stites & Harbison PLLC

20070032498 - Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species: The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070032500 - Therapeutic agents useful for treating pain: where Ar1, Ar2, R3, R4, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Nitro(cyano)vinylpiperazine Compound”); compositions comprising an effective amount of a Nitro(cyano)vinylpiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an... Agent: Jones Day

20070032501 - Aryl pyridines and methods of their use: Aryl pyridines, compositions comprising them, and methods of their use for the treatment, prevention and management of a variety of diseases and disorders are disclosed.... Agent: Lexicon Genetics Incorporated

20070032502 - Quinazoline derivatives useful in cancer treatment: y

20070032503 - Method of preparation of azaindole derivatives: A method of preparing azaindole compounds for antiviral use having the formula... Agent: Louis J. Wille Bristol-myers Squibb Company

20070032504 - Polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline: This invention relates to a novel compound having pharmacological activity, to processes for its preparation, to compositions containing it and to its use in the treatment of CNS and other disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070032505 - Crystalline form of gatifloxacin: The present invention relates to a crystalline form of gatifloxacin obtainable by a process that comprises recrystallisation of the crude gatifloxacin in methanol and which is stable with a water content ranging between 2.5 and 4.5% by weight, to a process for preparing it and to the use thereof as... Agent: Wolf Block Schorr And Solis-cohen LLP

20070032506 - Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride: The present invention relates to novel crystalline forms of (2R-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N, 1-trimethyl-alpha-oxo-1H-indole-3-acetamide monochloride, methods for their preparation, and pharmaceutical compositions comprising the novel pseudopolymorphs.... Agent: Philip S. Johnson Johnson & Johnson

20070032507 - Indolylmaleimide derivatives: which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose... Agent: Novartis Corporate Intellectual Property

20070032509 - New capped pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070032508 - Quinazoline derivatives as tyrosine kinase inhibitors: A quinazoline derivative of the formula (I); wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.... Agent: Morgan Lewis & Bockius LLP

20070032510 - Substituted pyrimidines as ligands of adenosine receptors: The invention provides a compound of formula (I) wherein R and R′ are selected from hydrogen, alkyl, alkenyl, alkynyl, or aryl; R″ and R′″ are selected from hydrogen, acyl, thio-acyl, seleno-acyl, alkyl, alkenyl, alkynyl, or aryl; or a pharmaceutically acceptable salt thereof, to interact with the adenosine receptors in the... Agent: Neurocrine Biosciences, Inc.

20070032511 - Amorphous ziprasidone mesylate: Provided is amorphous form of ziprasidone mesylate and process for its preparation. Also provided is a process for preparing ziprasidone mesylate dihydrate needle crystals.... Agent: Kenyon & Kenyon LLP

20070032512 - 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors: and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.... Agent: Osi Pharmaceuticals, Inc.

20070032513 - Quinazoline derivatives: The invention concerns quinazoline derivatives of the Formula I: (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use... Agent: Morgan Lewis & Bockius LLP

20070032514 - 2,4-diamino-pyrimidines as aurora inhibitors: e

20070032515 - Anaplastic lymphoma kinase modulators and methods of use: The present invention comprises compounds and pharmaceutical compositions comprising the compounds that are inhibitors of ALK. The invention also comprises methods of using the compounds and compositions to treat diseases mediated by ALK, including diseases such as cancer, immunological disorders, cardiovascular diseases, and other degenerative disorders.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070032516 - Use of tiotropium salts in the treatment of severe persistent asthma: The instant invention relates to the use of tiotropium salts for the manufacture of a medicament for the treatment of patients suffering from severe persistent asthma.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070032518 - Compounds and methods of use: Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The... Agent: Banner & Witcoff

20070032519 - Compounds modulating c-kit and c-fms activity and uses therefor: Compounds active on the receptor protein tyrosine kinases c-kit and c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or condition and c-fms-mediated diseases or condition, and methods for the use thereof.... Agent: Foley & Lardner LLP

20070032517 - Substituted naphthyridinone derivatives: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20070032520 - Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators: The present invention refers to new sulfonamide derivatives, of general formula (1a, 1b, 1c) optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070032521 - Use of c-kit inhibitors for treating type ii diabetes: The present invention relates to a method for treating type II diabetes, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be chosen from non-toxic, selective and potent c-kit inhibitors.... Agent: Foley And Lardner LLP Suite 500

20070032522 - Antiviral agents: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20070032523 - Chemical compounds: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.... Agent: Fish & Richardson P.C.

20070032524 - Diphenylmethyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, e, m, R1, R2, R3, R4a, R4b, R5, R6, R7 and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20070032525 - Piperidine derivatives having ccr3 antagonism: The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising... Agent: Sughrue Mion, PLLC

20070032526 - Cyclic derivatives as modulators of chemokine receptor activity: e

20070032527 - Method of inhibiting angiogenesis:

20070032528 - Heterocyclic compounds:

20070032530 - Phenylpyridine derivatives:

20070032529 - Pyrazole compounds and their use as antidiabetes agents: wherein Ring Q represents an aryl or heteroaromatic group, R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, R2 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or an azido group, R3 represents a halogen atom, a hydroxyl... Agent: Fitzpatrick Cella Harper & Scinto

20070032531 - Sphingosine kinase inhibitors and methods of their use: The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070032532 - Hsp90 family protein inhibitors: (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or... Agent: Fitzpatrick Cella Harper & Scinto

20070032533 - Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use: The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070032534 - Synthesis of epothilones, intermediates thereto and analogues thereof: e

20070032535 - Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof: Disclosed is a method for preparing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates thereof, such as the (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride salt via dynamic kinetic resolutions.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070032536 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by inhibiting the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070032537 - 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases: The present invention relates to certain pyrazole carboxylic acid and ester derivatives, and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the RUP25 receptor. (I) Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the... Agent: Arena Pharmaceuticals, Inc.

20070032538 - Use of compounds: The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of... Agent: Novartis Corporate Intellectual Property

20070032539 - Cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives serving as pesticides: e

20070032540 - Process for the preparation of ropinirole: A new process for the preparation of Ropinirole (1) and pharmaceutically acceptable hydrochloride salt thereof comprising reacting the compound (V) with nitromethane to obtain the compound of formula (II), which is reduced to compound (III) and alkylated to obtain compound (IV). The oxidation of the indole ring provides the compound... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070032541 - Cyclic derivatives as modulators of chemokine receptor activity: n

20070032542 - Process for the preparation of enantiopure pyrrolidin-2-one derivatives:

20070032543 - Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients: The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives and combinations of said derivatives with other therapeutically active ingredients. The invention also concerns compositions comprising said derivatives or said combinations and uses thereof, for the treatment of cerebrovascular diseases, pathology related to inflammation, neurodegeneration, deregulations of lipid and/or glucose metabolism, cell proliferation... Agent: Nixon & Vanderhye, PC

20070032544 - Medicinal acidic cannabinoids: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention... Agent: Banner & Witcoff, Ltd.

20070032545 - Antibiotic fki-1778 and process for producing the same: A microorganism belonging to filamentous fungi, capable of producing antibiotic FKI-1778A and/or FKI-1778B and/or FKI-1778C and/or FKI-1778D is cultured in a culture medium to thereby accumulate the antibiotic FKI-1778A and/or FKI-1778B and/or FKI-1778C and/or FKI-1778D in the culture mixture. The antibiotic FKI-1778A and/or FKI-1778B and/or FKI-1778C and/or FKI-1778D is collected... Agent: Young & Thompson

20070032546 - Novel formulations comprising fenofibrate and a statin, and related methods of treatment: The invention provides novel omega-3 oil formulations comprising fenofibrate and a statin. These formulations are effective in small volumes. Related methods of treatment are also described.... Agent: Philip S. Johnson Johnson & Johnson

20070032547 - Method and device for treating migraine, tension-type and post-traumatic headache, atypical facial pain, and cervical muscle hyperactivity: A new non-invasive, non-toxic, non-sedating method for treatment migraine, tension and post-traumatic headache, atypical facial pain, and cervical muscle hyperactivity (spasm) is presented. This method comprises the application of cold, through the use of a portable thermoelectric cooler, to an intra-oral area of tenderness which has been found to be... Agent: Evelyn M. Sommer

20070032548 - Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions: Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions.... Agent: Sheridan Ross PC

20070032549 - Process for obtaining hmg-coa reductase inhibitors of high purity: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura,... Agent: Bromberg & Sunstein LLP

20070032550 - Novel salts and methods for their preparation: Disulfonate salts of 2,4-pentanedione and methods for making such salts are described. The disulfonate salts are useful as cement dispersants. Cement compositions including such salts, methods for making cement compositions including such salts, and methods for performing cementing operations using such cement compositions are also described.... Agent: Craig W. Roddy Halliburton Energy Services

20070032551 - Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof: s

20070032552 - Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof:

20070032553 - Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome: The invention provides a method of treating a condition selected from hearing disorders, vestibular disorders, attention disorders, intention tremor and restless leg syndrome comprising administering to a human patient in need thereof a therapeutically effective amount of a compound which is an agonist at GABAA receptors which comprise an α... Agent: Merck And Co., Inc

20070032555 - Novel aryloxyphenyl-propanamines: The present invention relates to a non-radioactive, heavy-atom isotopologue of Compound 1 containing one or more deuterium in place of a hydrogen covalently bound to carbon. The Compound 1 isotopologues of the invention are inhibitors of norepinephrine uptake and possess unique biopharmaceutical and pharmacokinetic properties compared to the corresponding non-isotope... Agent: Edwards & Angell, LLP

20070032554 - Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors: Provided are methods and medicaments for treating stuttering or another communication disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.... Agent: Eli Lilly & Company

20070032556 - Aromatic polyamine derivative: wherein Ring Z represents a monocyclic or polycyclic aromatic ring; Ra, Rb, Rc, and Rd are each a substituent bonded to Ring Z, where Ra and Rb are the same as or different from each other and each represent a protected or unprotected amino group, and Rc and Rd are... Agent: Birch Stewart Kolasch & Birch

20070032557 - Method for administering levosimendan: The invention relates to intermittent administration of an inotropic agent (such as, but not limited to a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders, such as, pulmonary hypertension, myocardial ischemia, acute heart failure, chronic heart failure or acute on chronic heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070032558 - Method of treating herpes viral infections using a halogenated hydrocarbon composition: A method to reduce the incidence and time to healing of paraesthesia and skin lesions associated with herpes virus infections. In one form, the method of treatment involves topical application with an halogenated hydrocarbon alone, preferably ethyl chloride, which as a skin refrigerant, freezes the virus infected skin cells or... Agent: Brooks Kushman P.C.

20070027063 - Method of preserving the function of insulin-producing cells: Methods and compositions for preserving the function of insulin-producing cells and to furthering the lifespan of insulin-producing cells in non-insulin dependent patients with insulin-related disorders are provided.... Agent: Preston Gates & Ellis LLP

20070027064 - Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof: Methods for inhibiting metalloprotease activity; treating a pathological condition influenced by the action of MMP; treating a pathological condition influenced by cyclooxygenases, endonucleases, metallopepitidases and 5-epoxigenase; treating a pathological condition for which the presence of a metal ion is required; inhibiting the lethal factor produced by toxigenic strains of anthrax;... Agent: Martin Moynihan Prsti Inc

20070027065 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070027066 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070027067 - Transition-state inhibitors of pin1, alpha-ketoamide-containing peptidomimetics, and synthesis thereof: Novel α-ketoamide-containing peptidomimetics are provided, such as peptidomimetics containing an α-ketoamide Ser-Pro dipeptide analogue. The α-ketoamide is preferably incorporated into another molecule as a Pin1 inhibitor (such as a pentapeptide analogue Ac-Phe-Tyr-pSer-Pro-Arg-NH2).... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070027068 - Erythropoietin: remodeling and glycoconjugation of erythropoietin: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070027069 - Glucan-protein complex extracted from grifola (maitake): 1) a step of thermally extracting mycelia or fruit bodies of Grifola with water; 2) a step of adding alcohol to the obtained water-soluble extract fraction to a final concentration between 20% and 70% by volume, allowing the resulting solution to stand at a temperature between 1° C. and 25°... Agent: Davidson, Davidson & Kappel, LLC

20070027071 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck And Co., Inc

20070027070 - Medicinal uses of mu-opioid receptor agonists: The present invention provides methods for stimulating mu-opioid receptors with agonist peptides in a mammal in need thereof. The methods comprise administering to the mammal an effective amount of a selective mu-opioid receptor agonist peptide that comprises at least two α-amino acid residues. At least one of the amino acid... Agent: Hoffmann & Baron, LLP

20070027072 - Pharmaceutical compositions comprising cyclosporins: A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.... Agent: Allergan, Inc.

20070027075 - Compositions and methods for targeted drug delivery: The present invention provides for methods and compositions for transporting agents and macromolecules across biological membranes. In one embodiment, the invention relates to a method for enhancing transport of a selected agent across a biological membrane, wherein a biological membrane is contacted with a composition containing a biologically active rotaxane... Agent: Frost Brown Todd, LLC

20070027079 - Ghrp 2 strips: The products that exist on the market today that produce the same results are with injection. This new product, HGH Strips, is taken orally through strips that are placed on the back of the toungue. HGH Strips is scientifically developed with GHRP-2 (Growth Hormone Releasing Peptide-2), L-Lysine, L-Argenin and L-Valine... Agent: Lorn Leitman

20070027083 - Human growth hormone aqueous formulation: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.... Agent: Genentech, Inc.

20070027082 - Intracellular interleukin-1 receptor antagonist and uses thereof: Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over- expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix... Agent: Benjamin Aaron Adler, Ph.d., J.d.

20070027078 - Isolated proteins from a traditional chinese medicine yuzhu and use thereof: Disclosed is an isolated protein from the Chinese medicinal herb, Yuzhu, Polygonatum odoratum (Liliaceae). The protein disclosed is an effective agent showing potent antiviral activities while demonstrating antiproliferative effect on HL-60 leukemia and MCF-7 breast cancer cell lines in vitro. A method of obtaining the target protein and use thereof... Agent: Knobbe Martens Olson & Bear LLP

20070027073 - Long-acting derivatives of pyy agonists: The invention provides a PYY agonist derivative of the formula: (X)n-Z, wherein X is a radical 9-fluorenylmethoxy-carbonyl (Fmoc) or 2-sulfo-9-fluorenyl-methoxycarbonyl (FMS), Z is the residue of a PYY agonist linked to the radical X through an amino or hydroxyl group, and n is 1 to 3, or a pharmaceutically acceptable... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070027081 - Mechanisms of osteoinduction by lim mineralization protein-1 (lmp-1): The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070027080 - Method for treatment of vitiligo: Synergistic therapies for the treatment of vitiligo are provided. The major therapies for the treatment of vitiligo—a pigmentary disorder characterized by patchy depigmentation of skin are Psoralens plus UV-A, steroids. Basic fibroblast growth (bFGF) peptide lotion or surgical procedures. Psoralens plus UV-A is effective in about 50% of cases, steroids... Agent: The Webb Law Firm, P.C.

20070027085 - Microencapsulation and sustained release of biologically active polypeptides: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide, a sugar and... Agent: Andrea G. Reister, Esq. Covington & Burling

20070027084 - Novel integrin ligand itgl-tsp: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis,... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070027074 - Novel peptides that bind to the erythropoietin receptor: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also... Agent: Darby & Darby P.C.

20070027077 - Pharmaceutical compositions comprising factor vii polypeptides and factor xi polypeptides: Compositions comprising a factor VII or factor VII-related polypeptide and a factor XI or factor XI-related polypeptide, kits comprising the same, and methods of using such compositions (e.g., in the treatment of bleeding conditions) are provided... Agent: Novo Nordisk, Inc. Patent Department

20070027076 - Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma: According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these... Agent: Patent & Trademark Coordinator Legal Department

20070027086 - Melanocortin 1 receptor selective compounds: c

20070027087 - Methods for preventing mitochondrial permeability transition: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of... Agent: Hoffmann & Baron, LLP

20070027089 - Inhibitors of amyloid precursor protein processing: Disclosed is a method of using a compound as an inhibitor for β-secretase, wherein the compound is capable of binding to the site within the β-secretase recognition and/or cleavage site on amyloid precursor protein to specifically inhibit the β-secretase's activity to cleave amyloid precursor protein with maintaining its activities to... Agent: Jhk Law

20070027090 - Methods of treating cognitive dysfunction by modulating brain energy metabolism: Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed.... Agent: Lahive & Cockfield, LLP

20070027088 - Peptides and mimetics for reducing symptoms of toxic shock syndrome and septic shock: This invention relates to compositions and methods for providing protection against, or reducing the severity of, toxic shock syndrome, septic shock, food poisoning, and autoimmune diseases which are associated with toxin producing bacteria. This invention also relates to methods of using peptides, derivatives, mimetics, and antibodies for the prevention and... Agent: Morgan & Finnegan, L.L.P.

20070027091 - Novel melanocortin receptor agonists: Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R1 comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.... Agent: Novo Nordisk, Inc. Patent Department

20070027092 - Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture: a

20070027093 - Anorectic: The present invention relates to an anorectic containing a compound having a DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention provides an anti-obesity drug which is an anorectic that does not directly act on the... Agent: Leydig Voit & Mayer, Ltd

20070027094 - Inhibitors of nitric oxide synthase: The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of... Agent: Fulbright & Jaworski L.L.P.

20070027095 - Nicotinamide riboside kinase compositions and methods for using the same: The present invention relates to isolated nicotinamide riboside kinase (Nrk) nucleic acid sequences, vectors and cultured cells containing the same, and Nrk polypeptides encoded thereby. Methods for identifying individuals or tumors susceptible to nicotinamide riboside-related prodrug treatment and methods for treating cancer by administering an Nrk nucleic acid sequence or... Agent: Licata & Tyrrell P.C.

20070027096 - Aptamers to human epidermal growth factor receptor-3: The disclosure provided herein provides compositions of nucleic acid aptamers that bind human epidermal growth factor receptor-3 and methods for their use.... Agent: Gates & Cooper LLP Howard Hughes Center

20070027099 - Gene therapy of hbv infection via adeno-associated viral vector mediated long term expression of small hairpin rna (shrna): The invention provides a vector comprising an AAV-shRNA vector. The vector is preferably rAAV-151i/1694i. The invention also provides a method of suppressing or inhibiting HBV replication in liver cells infected therewith, comprising administering an amount of an AAVB-shRNA vector effective to suppress, inhibit or reduce HBV replication.... Agent: Cooper & Dunham, LLP

20070027098 - Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof: The invention relates to immunostimulatory oligonucleotide compositions. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can be administered in conjunction with an immunostimulatory peptide or antigen. Methods for modulating an immune response upon administration of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify... Agent: Morrison & Foerster LLP

20070027103 - Methods and compositions for silencing genes without inducing toxicity: The present invention provides methods of post-transcriptional gene silencing which involve the use of a first dsRNA having substantial sequence identity to a target nucleic acid and a short, second dsRNA which inhibits dsRNA-mediated toxicity. These methods can be used to prevent or treat a disease or infection by silencing... Agent: Clark & Elbing LLP

20070027102 - Methods and compositions for treating macular degeneration: This invention relates to methods of treating age-related macular degeneration (AMD). In particular, this invention provides methods of treating all forms of wet, age-related macular degeneration. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat wet AMD.... Agent: (osi) Eyetech, Inc.

20070027101 - Methods for treating ocular neovascular diseases: Disclosed herein are methods for treating ocular neovascular disease using anti-VEGF therapy in combination with a second therapy that inhibits the development of ocular neovascularization or destroys abnormal blood vessels in the eye, such as photodynamic therapy.... Agent: (osi) Eyetech, Inc.

20070027097 - Small interfering rna with improved activity: Chemically modified small interfering RNAs are described. Combinations of 2′-hydroxyl substitutions on the nucleotide riboses are shown to increase the longevity and extent of target gene knockdown in mammalian cells.... Agent: Mirus Corporation

20070027100 - Use of placental growth factor for preventing or treating ischemic diseases or stroke: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in... Agent: Peter Carmeliet

20070027104 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070027105 - Peroxide removal from drug delivery vehicle: The present invention is related to methods for lowering peroxide levels in sucrose acetate isobutyrate formulations and to composition used in and formed by such methods.... Agent: Woodcock Washburn LLP

20070027106 - Charged sophorolipids and sophorolipid containing compounds: e

20070027107 - Compositions and methods for treating estrogen-dependent diseases and conditions: A pharmaceutical composition for the treatment of an estrogen-dependent disease or condition comprises: (1) at least one polysaccharide selected from the group consisting of an alginate and a fucoidan in a quantity effective to treat an estrogen-dependent disease or condition; and (2) a pharmaceutically acceptable carrier. The composition can include... Agent: Catalyst Law Group, Apc

20070027108 - Method of producing effective bacterial cellulose-containing formulations: A new method to produce formulations of bacterial cellulose that exhibit improved viscosity-modifying properties particularly with low energy applied to effectuate viscosity changes therewith is provided. Such a method includes the novel co-precipitation with a water soluble co-agent that permits precipitation in the presence of excess alcohol to form an... Agent: J.m. Huber Corporation Legal Dept.

20070027109 - Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof: Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by... Agent: Jones Day

20070027110 - Double salts of (-)-hydroxycitric acid with an amine and a group ii a metal and a process for preparing the same: This invention relates to novel double salt of (−)-hydroxycitric acid with an amine and zinc or a group II A metal. These compounds are stable and water soluble and are used as nutraceuticals, weight reducing agents and in beverages. The double salts have the following general formula (I) Wherein X... Agent: Rader Fishman & Grauer PLLC

20070027111 - Immunomodulatory compounds and methods of use thereof: The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, therapeutic and prophylactic treatment of cancer, treating autoimmune conditions, treating allergic reactions and... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070027112 - Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions: The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae: (1) (2) wherein: Ar1 is independently a biphenyl, phenanthryl, fluorenyl, or carbazolyl, and is optionally substituted;... Agent: Nixon & Vanderhye, PC

20070027114 - Phosphonate analogs of antimetabolites: The invention is related to phosphorus substituted antimetabolites, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070027113 - Purine nucleoside phosphorylase inhibitory phosphonate compounds: The invention is related to phosphorus substituted purine nucleoside phosphorylase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070027115 - Triazole derivatives useful in therapy: e

20070027116 - Therapeutic phosphonate derivatives: Phosphorus substituted mycophenolate derivatives with anti-cancer, anti-viral, anti-inflammatory and anti-tissue/organ transplant rejection properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit tumor growth, viral growth, inflammation, and tissue/organ transplant rejection and/or are useful therapeutically for the treatment or prevention of cancer, viral infection, inflammation... Agent: Viksnins Harris & Padys Pllp

20070027117 - Novel glucocorticoid receptor ligands for the treatment of metabolic disorders: This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20070027118 - Novel compounds of amino sulfonyl derivatives: i

20070027119 - Antibacterial composition and method of use: Use of a liquid composition comprising at least two agents selected from lactic acid, salicylic acid, benzyl alcohol, and/or low molecular weight aliphatic alcohol having less than five carbon atoms for the manufacture of an antimicrobial solution is disclosed. In a preferred embodiment, the antimicrobial solution is formulated as a... Agent: Lathrop & Gage Lc

20070027120 - Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes: Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Other methods include intermittent... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070027122 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment... Agent: Ostrolenk Faber Gerb & Soffen

20070027123 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment... Agent: Ostrolenk Faber Gerb & Soffen

20070027124 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment... Agent: Ostrolenk Faber Gerb & Soffen

20070027121 - Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy: A method of treatment of symptoms associated with diarrhea-predominant IBS and nonconstipated IBS in a female subject receiving contraceptive therapy, which comprises administering a physiologically effective amount of cilansetron or a pharmaceutically acceptable derivative thereof.... Agent: Mayer, Brown, Rowe & Maw LLP

20070027125 - Cyanopyrrole-phenyl progesterone receptor modulators and uses thereof: m

20070027126 - Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof:

20070027127 - Treatment of inflammatory oral diseases with a combination of inhibitors of tnf-alpha and immunosuppressive agents: The invention provides methods for treating inflammatory oral diseases, involving administration of combinations of inhibitors of TNF-α and immunosuppressive agents.... Agent: Clark & Elbing LLP

20070027128 - Novel anti-inflammatory androstane derivative: e

20070027129 - Water-soluble compound: A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least... Agent: Buchanan, Ingersoll & Rooney PC

20070027130 - Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic: The present invention provides a β-lactam antibiotic such as cefepime and a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP /

20070027131 - Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins: Disclosed are compounds which bind α4 integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4 integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis,... Agent: Foley & Lardner LLP

20070027132 - Hydroxyalkanoylaminolactams and related structures as inhibitors of alphabeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20070027133 - Bicyclic pyrazolyl and imidazolyl compounds and uses thereof:

20070027134 - Crystal form of asenapine maleate: The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrole (Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form.... Agent: Akzo Nobel Inc. Intellectual Property Department

20070027135 - Apoptosis promoters: Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti-apoptotic family protein member are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070027136 - Formulations of anthraquinone derivatives: A stable, sterile aqueous solution of a compound of formula (I): in which A is a C alkylene group with a chain length between NH and N(O)R′R″ of at least 2 carbon atoms and R′ and R″ are each separately selected from C1-4 alkyl groups and C2-4 hydroxyalkyl and C2-4... Agent: Nixon & Vanderhye, PC

20070027137 - Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents: Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain.... Agent: Abelman, Frayne & Schwab

20070027138 - Derivatives and analogs of galanthamine: New compounds of general formula I... Agent: Popovich, Wiles & O'connell, PA 650 Third Avenue South

20070027141 - Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors: The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070027140 - N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes: e

20070027139 - Piperazinyl-quinoline derivatives useful for the treatment of cns disorders: This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070027142 - Diazepinoquinolines, synthesis thereof, and intermediates thereto: The present invention relates to methods for synthesizing compounds useful as 5HT2C agonists or partial agonists, derivatives thereof, and to intermediates thereto.... Agent: Choate, Hall & Stewart LLP

20070027143 - Novel substituted 2,3-benzodiazepine derivatives: The invention relates to new 2,3-benzodiazepine derivatives of formula (I), isomers and acid addition salts thereof and to pharmaceutical compositions containing the same, as well as to pharmaceutical compositions and methods of using the same suitable for treating conditions associated with muscle spasms, epilepsy, acute and chronic forms of neurodegenerative... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070027144 - Novel use of cannabinoid receptor agonist: e

20070027146 - Methods of treating nervous disorders: The invention relates to compositions and methods for treating nervous disorders. More particularly, the invention relates to methods of treating amyloïd beta peptide-related disorders, particularly Alzheimer's disease, using Rac1 inhibitors. The invention may be used in mammalian subjects, particularly human subjects, at various stages of the disease, including disease onset.... Agent: Nixon & Vanderhye, PC

20070027145 - Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases: The present invention relates to compounds of the Formula (I): wherein Z is —NH—, —O— or —S—; R1 represents bromo or chloro; R3 represents C1-3alkoxy or hydrogen; R2 is selected from one of the following three groups: (i) Q1X1- wherein X1 and Q1 are as defined herein; (ii) Q15W3— wherein... Agent: Morgan Lewis & Bockius LLP

20070027147 - Biarylurea derivatives: e

20070027148 - New enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments:

20070027149 - 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.... Agent: Pfizer Inc

20070027150 - 2-amino-quinazolin-5-ones: 2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at... Agent: Novartis Vaccines And Diagnostics Inc.

20070027151 - Heterocyclic compounds: R1 is aryl or heteroaryl; each of R2 and R4, independently, is H, halogen, CN, alkyl, ORa, or NRaRb; R3 is H, halogen, CN, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORa, OC(O)Ra, OC(O)NRaRb, NRaRb, NRaC(O)Rb, NRaS(O)RbN, RaS(O)2Rb, NRaC(O)NRbRc, NRaC(S)NRbRc, NRaC(NRb)NRcRd, NRaC(O)ORb, S(O)NRaRb, S(O)2NRaRb, S(O)Ra, S(O)2Ra, C(O)Ra, C(O)ORa, or C(O)NRaRb;... Agent: Edwards & Angell, LLP

20070027152 - Topical anti-pruritic compositions and methods of action of same: Topical anti-pruritic compositions and methods of using the same to treat pruritus. These anti-pruritic compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, and/or preventing pruritic skin conditions, as well as other related skin conditions. In a particular aspect, the present formulations provide a quicker and more effective... Agent: Nath & Associates

20070027153 - Topical skin-protectant and anti-pruritic compositions: Topical skin protectant compositions, and more particularly anti-pruritic skin protectant compositions, comprising a skin protective ingredient, a therapeutically effective amount of a pharmaceutically active agent comprising an anesthetic agent or derivative thereof, an oleaginous solvent comprising a substance other than the skin protective ingredient, and an aqueous solvent. These skin... Agent: Nath & Associates

20070027155 - Biaryl piperazinyl-pyridine analogues: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Edwards & Angell, LLP

20070027154 - Insecticide for agricultural or horticultural use and method of use thereof: e

20070027156 - Crf antagonists and heterobicyclic compounds: wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which... Agent: Sughrue Mion, PLLC

20070027157 - Quinoxalinone-3-one derivatives as orexin receptor antagonists: The invention relates to quinoxalinone derivatives of general Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Dickstein Shapiro LLP

20070027158 - High affinity small molecule c5a receptor modulators: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the... Agent: Edwards & Angell, LLP Intellectual Property Practice Group

20070027159 - Therapeutic agents useful for treating pain: wherein Ar1, Ar2, V, X, R3, R4, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering... Agent: Jones Day

20070027160 - Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor: The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP /

20070027161 - Aryloxy quinolines and uses thereof: e

20070027162 - Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride: The present invention is directed to crystal and amorphous forms of the 5-HT1A receptor antagonist 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride, as well as compositions thereof and methods of using the same.... Agent: Cozen O' Connor, P. C.

20070027163 - Indol-3-y-carbonyl-piperidin and piperazin-derivatives: wherein the residues R1 to R3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070027164 - Agents for treating neurodegenerative diseases: The present invention relates to compounds effective in preventing neuronal cell death, which may be used in the treatment of neurodegenerative diseases. It is based, at least in part, on the discovery that particular compounds were effective in preventing neuronal death in model systems of Huntington's Disease.... Agent: Baker & Botts L.L.P.

20070027165 - Fungicidal mixtures for controlling rice pathogens: e

20070027166 - Pyrazolo pyrimidines useful as aurora kinase inhibitors: wherein one of is a double bond, as valency permits; and R2, R4, X1A, X2A, X1B, X2B, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein... Agent: Choate, Hall & Stewart LLP

20070027167 - Use of c-src inhibitors alone or in combinaton with sti571 for the treatment of leukaemia: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the... Agent: Novartis Corporate Intellectual Property

20070027168 - 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals: The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070027169 - Xiap-targeted prostate cancer therapy: A treatment for prostate cancer using cyclin-dependent kinase inhibitors is provided. The effects of cyclin-dependent kinase inhibitors on the survival of prostate cancer cells was examined. Roscovitine, R-roscovitine, and CGP74514A were shown to induce the apoptosis of LNCaP and LNCaP-Rf cells, both of which express wild-type p53. The cyclin-dependent kinase... Agent: Smith Hopen, Pa

20070027170 - Process for preparing amino crotonyl compounds: An improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070027171 - Cycloalkanepyrrolopyridines as dp receptor antagonists: Novel cycloalkanepyrrolopyridine derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.... Agent: Merck And Co., Inc

20070027172 - Crystalline pharmaceutical: New crystalline forms of lopinavir are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070027173 - Indol-3-yl-carbonyl-spiro-piperidine derivatives as vla receptor antagonists: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070027174 - Phenylalanine enamide derivatives: or Rz is an atom or group as previously defined and Rx and Ry are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and... Agent: Woodcock Washburn LLP

20070027175 - Antineoplastic activities of ellipticine and its derivatives: The present invention describes selective cell growth inhibition of myeloma cells by ellipticine derivatives, 9-methoxy ellipticine and 9-dimethyl amino-ethoxy ellipticine. The cell growth inhibition efficacy was highest for 9-dimethyl amino-ethoxy ellipticine among the ellipcitine derivatives tested. The cell toxicity of 9-dimethyl amino-ethoxy ellipticine was selective for myeloma cells and did... Agent: Benjamin Aaron Adler Adler & Associates

20070027176 - Compositions for veterinary and medical applications: e

20070027177 - Isoquinolinone potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20070027178 - Substituted tetrahydro-1h-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists: The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation... Agent: Louis J. Wille Bristol-myers Squibb Company

20070027179 - Azaindole derivatives, preparations thereof, uses thereof and compositions containing them: Compounds of formula I or pharmaceutically acceptable salts thereof Formula (I) wherein Ar, R1, R2, R3, Ra, Rb and X are as defined in the specificationas well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070027180 - Process for preparing zolpidem: A process for preparing zolpidem.... Agent: Dr. Reddy's Laboratories, Inc.

20070027181 - Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food: p

20070027182 - Octahydroisoquinoline compounds as opioid receptor modulators: Compounds which bind to opioid receptors are provided. In a preferred embodiment of the invention, the compounds are opioid receptor antagonists. The present invention also provides methods of treating conditions which are mediated by an opioid receptor.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070027183 - Inhibitors of microsomal triglyceride transfer protein and apo-b secretion: The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates... Agent: Edwards & Angell, LLP

20070027184 - Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease: Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of... Agent: International Patent Group Attn: Ms Lavern Hall

20070027185 - Antithrombotic aromatic ethers: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and... Agent: Eli Lilly & Company

20070027186 - Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones: i

20070027187 - Hydroxy-tetrahydro-naphthalenylurea derivatives: This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VR1 antagonist and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the... Agent: Jeffrey M. Greenman

20070027188 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient This invention also relates to the use of such compounds to provide a... Agent: Merck And Co., Inc

20070027189 - Use of known active ingredients as radical scavengers: The invention relates to the use of certain proton pump inhibitors in the treatment of pathological manifestations induced or influenced by free radicals.... Agent: Nath & Associates PLLC

20070027190 - Antibacterial fab i inhibitors: Disclosed herein are antibacterial compounds that inhibit fabl, a NADH-dependent enoyl [acyl carrier protein] reductase enzyme in the fatty acid biosynthesis pathway. The compounds are represented by structural formulas Ia and Ib: R1 and R2 are independently monocyclic aryl or heteroaryl groups, wherein the groups represented by R1 and R2... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070027191 - Polysubstituted 1,1-pyridyloxycyclopropanamine compounds: R5 and R6 represent a hydrogen atom, or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl, (C1-C6)trihaloalkoxy or optionally substituted amino group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of... Agent: The Firm Of Hueschen And Sage

20070027192 - Polysubstituted 1,1-pyridylamioncyclopropanamine compounds:

20070027193 - Method of identifying inhibitors of dhodh: The present invention provides a compound capable of binding to the ubiquinone binding site of DHODH which contains a non-aromatic ring system as a core structure, a group capable of interacting with structural elements of subsite 2 or 3 of the ubiquinone binding site of DHODH and a group capable... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070027195 - Novel compositions comprising higher primary alcohols and nicottinic acid and process of preparation thereof: A composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and nicotinic acid, its salts or derivatives thereof optionally with excipients, and process of preparation of... Agent: Ladas & Parry

20070027194 - Treatment of actinic keratoses with calcium channel blockers: The present invention relates to methods and compositions for the treatment and/or prevention of actinic keratoses comprising a calcium channel blocking compound.... Agent: Fulbright & Jaworski L.L.P.

20070027196 - Activator of peroxisome proliferator-activated receptor delta: (wherein A represents O or S; B1 represents N, etc.; B2 represents O, etc.; each of X1 and X2 represents O, S, a bond, etc.; Y represents C1-8 alkylene chain; z represents O or S; R1 represents aryl, etc. which can have substituents; R2 represents C1-8 alkyl, etc.; R3 represents... Agent: Jones Day

20070027197 - Pharmaceutical composition and method for the treatment of diseases using hmg-coa reductase inhibitors and insulin secretion enhancers or sensitizers: The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) a HMG-CoA reductase inhibitor or a or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or  (b) an insulin sensitizer or a pharmaceutically acceptable salt... Agent: Novartis Corporate Intellectual Property

20070027198 - Crystal of heterocyclic compound: The main purpose of the invention is to provide a new specific crystal of 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-r-2-carboxylic acid. The invention includes, for example, a crystal of 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-r-2-carboxylic acid, which has peaks at the angles of diffraction of at least 12.4°, 17.1°, and 20.8° in a powder X-ray diffraction spectrum, and a preventive... Agent: Greenberg Traurig

20070027199 - Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation: e

20070027200 - Bis-benzimidazoles and related compounds as potassium channel modulators: The present invention provides a genus of bis-benzimidazole compounds, methods and pharmaceutical compositions that are useful as modulators of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.... Agent: Townsend And Townsend And Crew, LLP

20070027201 - Use of progesterone receptor modulators: wherein R1, R2, R3, R4, R5, R6 and R7, are as defined herein, for contraception, hormone replacement therapy, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, treating uterine myometrial fibroids, treating endometriosis, treating benign prostatic hypertrophy, treating carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, and meningioma,... Agent: Howson And Howson Cathy A. Kodroff

20070027202 - Process for the preparation of carvedilol and its salts: Disclosed herein is a process for preparation of carvedilol substantially free from its bis-impurity comprises the reaction of 4-(2,3-epoxypropoxy)carbazole and 2-(2-methoxyphenoxy)ethylamine in a polar aprotic solvent media; followed by isolation of carvediol from the reaction mass as an acid addition salt and subsequent conversion into pure carvedilol.... Agent: Blank Rome LLP

20070027203 - Method of treating inflammatory arthritis: The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-α or NATURA. The present invention is further... Agent: Rodney J. Fuller Fennemore Craig

20070027204 - 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives: e

20070027205 - Diarylmethyl derivatives as potassium channel modulators: This invention relates to novel compounds useful as potassium channel modulators. More specifically the invention provides chemical compounds useful as modulators of SKCa and/or IKCa channels.... Agent: Birch Stewart Kolasch & Birch

20070027206 - Iminocarboxylic acid salt-containing solid composition and production method thereof: To provide a solid composition as follows: exhibiting excellent stability; having advantages for transportation and storage; containing no additives; exhibiting functions such as excellent detergency, and capable of being preferably used, and a production method thereof. A solid composition comprising an iminocarboxylic acid salt, wherein the iminocarboxylic acid salt is... Agent: Connolly Bove Lodge & Hutz LLP

20070027207 - Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel: A process is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel, in particular, the semi-synthesis of protected taxane intermediates.... Agent: Cindy A. Lynch Conor Medsystems, Inc.

20070027208 - Antiparkinsonian action of phenylisopropylamines: A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat... Agent: Myers Bigel Sibley & Sajovec

20070027209 - Prevention and treatment of atherosclerosis with lithospermate b: This invention relates to lithospermate B (‘LAB’ hereinafter) that inhibits proliferation and migration of vascular smooth muscle cells (‘VSMC’ hereinafter). More specifically, this invention relates to a pharmaceutical composition comprising LAB isolated from Salviae miltiorrhiza as an active ingredient for treating atherosclerosis.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070027210 - Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070027211 - Process for production of bicalutamide: A process which includes the reacting of sodium perborate with N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)thio]-2-hydroxy-2-methylpropanamide to form bicalutamide. The process is efficient, inexpensive, environmentally friendly and produces bicalutamide in good yield.... Agent: Ivor M. Hughes, Barrister & Solicitor, Patent & Trademark Agents

20070027212 - Alpha 2 delta ligands for fibromyalgia and other disorders: R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The... Agent: Pfizer Inc.

20070027213 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Hunton & Williams LLP Intellectual Property Department

20070027214 - Orally administered agent for improving skin condition: It is desirable to provide a medicament and a nutritional food to improve skin conditions and to create fulfilling life for people who are not satisfactory about their skin conditions. Specifically, one object of the present invention is to provide an orally administered agent, a food and drink, or a... Agent: Darby & Darby P.C.

20070027215 - Nuclear receptor ligands and ligand binding domains: The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as “TR”). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.... Agent: Quine Intellectual Property Law Group, P.C.

20070027216 - Novel hydrochloride salts of levodopa: The present invention provides a novel hydrochloride salt of levodopa. In addition, pharmaceutical compositions comprising said hydrochloride salt of levodopa may be used as fast-dissolve compositions. Methods of making and of using the same are also provided.... Agent: Philip S. Johnson Johnson & Johnson

20070027217 - Composition and method for preventing secondary burn ischemia: A cream composition for the topical application of ibuprofen to prevent secondary burn ischemia, inducing changes in the dynamics of blood flow in the region of application. The cream composition includes approximately 0.5 g of 1% ibuprofen cream. A single application of ibuprofen cream to the surface of a skin... Agent: Stainbrook & Stainbrook, LLP

20070027218 - Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from 24 to 39 carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and ezetimibe, its salts, analogs or derivatives thereof optionally with pharmaceutically acceptable excipients, and... Agent: Ladas & Parry